

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
AAAS	Achalasia-addisonianism-alacrimia syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
ABCA12	Congenital ichthyosis, ABCA12-related	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
ABCA3	Surfactant metabolism dysfunction, pulmonary 3	AR	General Population	1 in 116	99%	1 in 11,501	1 in 5,336,464
ABCA4	Stargardt disease	AR	General Population	1 in 51	98%	1 in 2,501	1 in 510,204
ABCB11	Progressive familial intrahepatic cholestasis	AR	General Population	1 in 112	98%	1 in 5,551	1 in 2,486,848
ABCB4	Progressive familial intrahepatic cholestasis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
ABCC8	Familial hyperinsulinism	AR	General Population	1 in 112	98%	1 in 5,551	1 in 2,486,848
			Ashkenazi Jewish Population	1 in 44	98%	1 in 2,151	1 in 378,576
			Finnish Population	1 in 25	98%	1 in 1,201	1 in 120,100
			Middle-Eastern Population	1 in 25	98%	1 in 1,201	1 in 120,100
ABCD1	Adrenoleukodystrophy, X-linked	XL	General Population	1 in 21,000	99%	1 in 2,099,901	1 in 8,399,804
ABCD4	Methylmalonic aciduria and homocystinuria, cblJ type	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
ACAD9	Acyl-CoA dehydrogenase-9 (ACAD9) deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
ACADM	Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency	AR	General Population	1 in 69	98%	1 in 3,401	1 in 938,676
			Caucasian / European Population	1 in 52	99%	1 in 5,101	1 in 1,061,008
			East Asian Population	1 in 198	99%	1 in 19,701	<1 in 10 million
			Native American Population	1 in 43	96%	1 in 1,051	1 in 180,772
ACADS	Short-chain acyl-coA dehydrogenase (SCAD) deficiency	AR	General Population	1 in 85	99%	1 in 8,401	1 in 2,856,340
			African/African American Population	1 in 52	99%	1 in 5,101	1 in 1,061,008
			Caucasian / European Population	1 in 76	99%	1 in 7,501	1 in 2,280,304
			Middle-Eastern Population	1 in 52	99%	1 in 5,101	1 in 1,061,008
			South Asian/Indian Population	1 in 51	99%	1 in 5,001	1 in 1,020,204
ACADSB	Short branched chain acyl-CoA dehydrogenase (SBCAD) deficiency	AR	General Population	1 in 368	99%	1 in 36,701	<1 in 10 million
			Hmong Population	1 in 6	99%	1 in 501	<1 in 10 million
ACADVL	Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency	AR	General Population	1 in 118	93%	1 in 1,672	1 in 789,184
			Middle-Eastern Population	1 in 74	93%	1 in 1,044	1 in 309,024
			Native American Population	1 in 61	93%	1 in 858	1 in 209,352
			South Asian/Indian Population	1 in 73	93%	1 in 1,030	1 in 300,760
ACAT1	3-ketothiolase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
ACOX1	Peroxisomal acyl-CoA oxidase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
ACSF3	Combined malonic and methylmalonic aciduria	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
ADA	Adenosine deaminase deficiency	AR	General Population	1 in 224	93%	1 in 3,187	1 in 2,855,552
ADAMTS2	Ehlers-Danlos syndrome, dermatosparaxis type	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 248	98%	1 in 12,351	<1 in 10 million
ADGRG1	Bilateral frontoparietal polymicrogyria	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
ADGRV1	Usher syndrome, type IIC	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
ADK	Hypermethioninemia due to adenosine kinase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
AFF2	Fragile XE syndrome	XL	General Population	<1 in 50,000	98%	1 in 2,499,951	1 in 9,999,804
AGA	Aspartylglucosaminuria	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Finnish Population	1 in 71	98%	1 in 3,501	1 in 994,284
AGL	Glycogen storage disease type III	AR	General Population	1 in 158	95%	1 in 3,141	1 in 1,985,112
			Faroese Population	1 in 28	95%	1 in 541	1 in 60,592
			Inuit Population	1 in 25	95%	1 in 481	1 in 48,100
			North African Jewish Population	1 in 37	95%	1 in 721	1 in 106,708
AGPAT2	Congenital generalized lipodystrophy, type 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
AGPS	Rhizomelic chondrodysplasia punctata, type 3	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
AGXT	Primary hyperoxaluria type 1	AR	General Population	1 in 120	99%	1 in 11,901	1 in 5,712,480
			Caucasian / European Population	1 in 173	99%	1 in 17,201	<1 in 10 million
AHCY	Hypermethioninemia due to deficiency of S-adenosylhomocysteine hydrolase	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
AHI1	Joubert syndrome, AHI1-related	AR	General Population	1 in 448	99%	1 in 44,701	<1 in 10 million
AIMP1	Hypomyelinating leukodystrophy 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
AIP1	Childhood-onset severe retinal dystrophy, AIP1-related	AR	General Population	1 in 409	99%	1 in 40,801	<1 in 10 million
AIRE	Autoimmune polyendocrinopathy syndrome type I	AR	General Population	1 in 150	98%	1 in 7,451	1 in 4,470,600
			Finnish Population	1 in 79	98%	1 in 3,901	1 in 1,232,716
AK2	Reticular dysgenesis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>AKR1D1</i>	Congenital Bile Acid Synthesis Defect	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ALDH3A2</i>	Sjögren-Larsson syndrome	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
<i>ALDH4A1</i>	Hyperprolinemia type II	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ALDH7A1</i>	Pyridoxine-dependent epilepsy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ALDOB</i>	Hereditary fructose intolerance	AR	General Population	1 in 122	99%	1 in 12,101	1 in 5,905,288
			African/African American Population	1 in 250	99%	1 in 24,901	<1 in 10 million
			Caucasian / European Population	1 in 67	99%	1 in 6,601	1 in 1,769,068
			Middle-Eastern Population	1 in 97	99%	1 in 9,601	1 in 3,725,188
<i>ALG6</i>	Congenital disorder of glycosylation type Ic	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>ALMS1</i>	Alstrom syndrome	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>ALOX12B</i>	Autosomal recessive, congenital, ichthyosis 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ALOXE3</i>	Congenital ichthyosiform erythroderma	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ALPL</i>	Hypophosphatasia	AR	General Population	1 in 158	95%	1 in 3,141	1 in 1,985,112
			Caucasian / European Population	1 in 274	95%	1 in 5,461	1 in 5,985,256
			Mennonite Population	1 in 25	95%	1 in 481	1 in 48,100
<i>AMH</i>	Persistent mullerian duct syndrome, type I	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>AMHR2</i>	Persistent mullerian duct syndrome, type II	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>AMN</i>	Megaloblastic anemia 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>AMPD2</i>	Pontocerebellar hypoplasia type 9	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>AMT</i>	Glycine encephalopathy	AR	General Population	1 in 373	98%	1 in 18,601	<1 in 10 million
			Finnish Population	1 in 117	98%	1 in 5,801	1 in 2,714,868
<i>ANO10</i>	Spinocerebellar ataxia 10	AR	General Population	1 in 93	99%	1 in 9,201	1 in 3,422,772
<i>ANO5</i>	Gnathodiaphyseal dysplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ANTXR2</i>	Hyaline fibromatosis syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>AP1S1</i>	MEDNIK syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>AP1S2</i>	X-linked Intellectual disability, AP1S2-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>AP3B1</i>	Hermansky-Pudlak syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>AP3D1</i>	Hermansky-Pudlak syndrome 10	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>APOPT1</i>	Mitochondrial complex IV deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>AQP2</i>	Nephrogenic diabetes insipidus	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			Finnish Population	1 in 169	95%	1 in 3,361	1 in 2,272,036
<i>AR</i>	Androgen insensitivity syndrome	XL	General Population	1 in 14,286	98%	1 in 714,251	1 in 1,428,571
<i>ARG1</i>	Arginase deficiency	AR	General Population	1 in 296	98%	1 in 14,751	<1 in 10 million
<i>ARL13B</i>	Joubert syndrome, ARL13B-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ARSA</i>	Metachromatic leukodystrophy	AR	General Population	1 in 100	99%	1 in 9,901	1 in 3,960,400
			Caucasian / European Population	1 in 78	99%	1 in 7,701	1 in 2,402,712
			Yemenite Jewish Population	1 in 75	99%	1 in 7,401	1 in 2,220,300
<i>ARSB</i>	Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
			Western Australian Population	1 in 283	98%	1 in 14,101	<1 in 10 million
<i>ARSE</i>	Chondrodysplasia punctata type 1, X-linked	XL	General Population	1 in 250,000	98%	1 in 12,499,951	<1 in 10 million
<i>ARX</i>	X-linked intellectual disability, ARX-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>ASL</i>	Argininosuccinate lyase deficiency	AR	General Population	1 in 132	90%	1 in 1,311	1 in 692,208
<i>ASNS</i>	Asparagine synthetase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Iranian Jewish Population	1 in 80	99%	1 in 7,901	1 in 2,528,320
<i>ASPA</i>	Canavan disease	AR	General Population	1 in 300	97%	1 in 9,968	<1 in 10 million
			Ashkenazi Jewish Population	1 in 55	96%	1 in 1,351	1 in 297,220
<i>ASS1</i>	Citrullinemia	AR	General Population	1 in 119	96%	1 in 2,951	1 in 1,404,676
			East Asian Population	1 in 132	96%	1 in 3,276	1 in 1,729,728
<i>ATM</i>	Ataxia-telangiectasia	AR	General Population	1 in 100	92%	1 in 1,239	1 in 495,600
<i>ATP13A2</i>	Kufor-Rakeb syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ATP6V0A2</i>	Cutis laxa, type IIA	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ATP6V0A4</i>	Renal tubular acidosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ATP6V1B1</i>	Renal tubular acidosis with deafness	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>ATP6V1E1</i>	Cutis laxa, type IIC	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ATP7A</i>	Menkes disease	XL	General Population	1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>ATP7B</i>	Wilson disease	AR	General Population	1 in 87	98%	1 in 4,301	1 in 1,496,748
			Caucasian / European Population	1 in 42	98%	1 in 2,051	1 in 344,568
			Ashkenazi Jewish Population	1 in 70	98%	1 in 3,451	1 in 966,280
<i>ATP8B1</i>	Progressive familial intrahepatic cholestasis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ATRX</i>	Alpha thalassemia X-linked intellectual disability syndrome	XL	General Population	<1 in 250,000	99%	1 in 24,999,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>AVPR2</i>	Nephrogenic diabetes insipidus	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>B9D1</i>	Joubert syndrome 27	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>B9D2</i>	Meckel syndrome 10	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BBS1</i>	Bardet-Biedl syndrome type 1	AR	General Population	1 in 367	99%	1 in 36,601	<1 in 10 million
<i>BBS10</i>	Bardet-Biedl syndrome type 10	AR	General Population	1 in 395	99%	1 in 39,401	<1 in 10 million
<i>BBS12</i>	Bardet-Biedl syndrome type 12	AR	General Population	1 in 791	99%	1 in 79,001	<1 in 10 million
<i>BBS2</i>	Bardet-Biedl syndrome 2	AR	General Population	1 in 621	99%	1 in 62,001	<1 in 10 million
<i>BBS2</i>	Retinitis Pigmentosa 74	AR	Ashkenazi Jewish Population	1 in 107	99%	1 in 10,601	1 in 4,537,228
<i>BBS5</i>	Bardet-Biedl syndrome 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BBS7</i>	Bardet-Biedl syndrome 7	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BBS9</i>	Bardet-Biedl syndrome 9	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BCHE</i>	Butyrylcholinesterase deficiency	AR	General Population	1 in 28	99%	1 in 2,701	1 in 302,512
<i>BCKDHA</i>	Maple syrup urine disease type Ia	AR	General Population	1 in 321	98%	1 in 16,001	<1 in 10 million
<i>BCKDHA</i>	Maple syrup urine disease type Ia	AR	Mennonite Population	1 in 10	98%	1 in 451	1 in 18,040
<i>BCKDHB</i>	Maple syrup urine disease type Ib	AR	General Population	1 in 364	98%	1 in 18,151	<1 in 10 million
<i>BCKDHB</i>	Maple syrup urine disease type Ib	AR	Ashkenazi Jewish Population	1 in 97	98%	1 in 4,801	1 in 1,862,788
<i>BCS1L</i>	Björnstad syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>BCS1L</i>	GRACILE syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>BCS1L</i>	Mitochondrial complex III deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>BLM</i>	Bloom syndrome	AR	General Population	1 in 800	87%	1 in 6,147	<1 in 10 million
<i>BLM</i>	Bloom syndrome	AR	Ashkenazi Jewish Population	1 in 134	99%	1 in 13,301	1 in 7,129,336
<i>BLOC1S3</i>	Hermansky-Pudlak syndrome 8	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BLOC1S6</i>	Hermansky-Pudlak syndrome 9	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BMP1</i>	Osteogenesis imperfecta, type XIII	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BMPER</i>	Diaphanospondylosostosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>BRIP1</i>	Fanconi anemia group J	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>BRWD3</i>	X-linked intellectual disability, BRWD3-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>BSND</i>	Bartter syndrome	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>BTD</i>	Biotinidase deficiency	AR	General Population	1 in 124	99%	1 in 12,301	1 in 6,101,296
<i>BTD</i>	Biotinidase deficiency	AR	Caucasian / European Population	1 in 71	99%	1 in 7,001	1 in 1,988,284
<i>BTD</i>	Biotinidase deficiency	AR	Latino Population	1 in 136	99%	1 in 13,501	1 in 7,344,544
<i>BTD</i>	Biotinidase deficiency	AR	Middle-Eastern Population	1 in 55	99%	1 in 5,401	1 in 1,188,220
<i>BTK</i>	X-linked agammaglobulinemia	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>C19orf12</i>	Mitochondrial membrane protein-associated neurodegeneration	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>C8orf37</i>	Bardet-Biedl Syndrome 21	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CAD</i>	Early Infantile Epileptic Encephalopathy 50	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CANT1</i>	Desbuquois dysplasia 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CAPN3</i>	Limb-girdle muscular dystrophy type 2A	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CAPN3</i>	Limb-girdle muscular dystrophy type 2A	AR	Caucasian / European Population	1 in 103	98%	1 in 5,101	1 in 2,101,612
<i>CASP14</i>	Congenital Ichthyosis 12	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CASQ2</i>	Catecholaminergic polymorphic ventricular tachycardia	AR	General Population	1 in 224	99%	1 in 22,301	<1 in 10 million
<i>CAVIN1</i>	Congenital Generalized Lipodystrophy 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CBS</i>	Homocystinuria due to cystathionine beta-synthase deficiency	AR	General Population	1 in 224	99%	1 in 22,301	<1 in 10 million
<i>CBS</i>	Homocystinuria due to cystathionine beta-synthase deficiency	AR	Caucasian / European Population	1 in 86	99%	1 in 8,501	1 in 2,924,344
<i>CBS</i>	Homocystinuria due to cystathionine beta-synthase deficiency	AR	Middle-Eastern Population	1 in 21	99%	1 in 2,001	1 in 168,084
<i>CC2D1A</i>	Autosomal recessive intellectual developmental disorder 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CC2D2A</i>	Joubert syndrome 9	AR	General Population	1 in 201	99%	1 in 20,001	1 in 16,080,804
<i>CCDC103</i>	Primary ciliary dyskinesia, type 17	AR	General Population	1 in 316	98%	1 in 15,751	<1 in 10 million
<i>CCDC151</i>	Primary ciliary dyskinesia, type 30	AR	General Population	1 in 365	98%	1 in 18,201	<1 in 10 million
<i>CCDC39</i>	Primary ciliary dyskinesia, type 14	AR	General Population	1 in 211	98%	1 in 10,501	1 in 8,862,844
<i>CCDC8</i>	3-M Syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CCDC88C</i>	Congenital hydrocephalus 1	AR	General Population	1 in 137	99%	1 in 13,601	1 in 7,453,348
<i>CD247</i>	Severe Combined Immunodeficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CD3D</i>	Severe Combined Immunodeficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CD3E</i>	Severe Combined Immunodeficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>CD3G</i>	Severe Combined Immunodeficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CD40LG</i>	Hyper IgM syndrome, X-linked	XL	General Population	1 in 50,000	98%	1 in 2,499,951	1 in 9,999,904
<i>CD8A</i>	Familial CD8 Deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CDAN1</i>	Dyserythropoietic congenital anemia, type Ia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CDCA7</i>	Immunodeficiency-centromeric instability-facial anomalies syndrome 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CDH23</i>	Usher syndrome, type 1D	AR	General Population	1 in 285	90%	1 in 2,841	1 in 11,364
<i>CEP104</i>	Joubert syndrome 25	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CEP152</i>	Seckel syndrome 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CEP152</i>	Microcephaly 9	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CEP290</i>	Joubert syndrome 5	AR	General Population	1 in 190	98%	1 in 9,451	1 in 7,182,760
<i>CEP290</i>	Leber congenital amaurosis 10	AR	General Population	1 in 190	98%	1 in 9,451	1 in 7,182,760
<i>CEP290</i>	Bardet-Biedl syndrome 14	AR	General Population	1 in 190	98%	1 in 9,451	1 in 7,182,760
<i>CEP290</i>	CEP290-related disorders	AR	General Population	1 in 190	98%	1 in 9,451	1 in 7,182,760
<i>CEP290</i>	Senior-Løken syndrome 6	AR	General Population	1 in 190	98%	1 in 9,451	1 in 7,182,760
<i>CEP290</i>	Meckel syndrome 4	AR	General Population	1 in 190	98%	1 in 9,451	1 in 7,182,760
<i>CERKL</i>	Retinitis pigmentosa 26	AR	General Population	1 in 148	98%	1 in 7,351	1 in 4,351,792
<i>CERS3</i>	Congenital ichthyosis 9	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CFTR</i>	Cystic Fibrosis	AR	General Population	1 in 32	99%	1 in 3,101	1 in 396,928
			African/African American Population	1 in 61	99%	1 in 6,001	1 in 1,464,244
			Ashkenazi Jewish Population	1 in 24	99%	1 in 2,301	1 in 220,896
			Caucasian / European Population	1 in 25	99%	1 in 2,401	1 in 240,100
			East Asian Population	1 in 94	99%	1 in 9,301	1 in 3,497,176
			Latino Population	1 in 58	99%	1 in 5,701	1 in 1,322,632
<i>CHAT</i>	Congenital myasthenic syndrome 6	AR	General Population	1 in 197	99%	1 in 19,601	<1 in 10 million
<i>CHM</i>	Choroideremia	XL	General Population	1 in 25,000	95%	1 in 499,981	1 in 1,999,964
<i>CHRNE</i>	Congenital myasthenic syndrome	AR	General Population	1 in 408	99%	1 in 40,701	<1 in 10 million
<i>CHRNA3</i>	Multiple pterygium syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CHST6</i>	Macular corneal dystrophy, CHST6-related	AR	General Population	1 in 79	99%	1 in 7,801	1 in 2,465,116
<i>CIITA</i>	Bare lymphocyte syndrome, type II	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CLCF1</i>	Crisponi cold-induced sweating syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CLCN1</i>	Autosomal recessive congenital myotonia	AR	General Population	1 in 176	99%	1 in 17,501	1 in 12,320,704
<i>CLCNKB</i>	Bartter syndrome	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CLCNKB</i>	Bartter syndrome type 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CLN3</i>	Neuronal ceroid lipofuscinosis	AR	General Population	1 in 230	98%	1 in 11,451	<1 in 10 million
			Finnish Population	1 in 72	98%	1 in 3,551	1 in 1,022,688
<i>CLN5</i>	Neuronal ceroid lipofuscinosis 5	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			Finnish Population	1 in 115	95%	1 in 2,281	1 in 1,049,260
<i>CLN6</i>	Neuronal ceroid lipofuscinosis, CLN6-related	AR	General Population	<1 in 500	92%	1 in 6,239	<1 in 10 million
<i>CLN8</i>	Neuronal ceroid lipofuscinosis, CLN8-related	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			Finnish Population	1 in 135	95%	1 in 2,681	1 in 1,447,740
<i>CLP1</i>	Pontocerebellar hypoplasia type 10	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CLRN1</i>	Usher syndrome, type 3A	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 120	98%	1 in 5,951	1 in 2,856,480
			Finnish Population	1 in 70	98%	1 in 3,451	1 in 966,280
<i>CNGA1</i>	Retinitis Pigmentosa, CNGA1-related	AR	General Population	1 in 210	99%	1 in 20,901	<1 in 10 million
<i>CNGA3</i>	Leber congenital amaurosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CNGB1</i>	Retinitis Pigmentosa, CNGB1-related	AR	General Population	1 in 296	99%	1 in 29,501	<1 in 10 million
<i>CNGB3</i>	Achromatopsia	AR	General Population	1 in 87	99%	1 in 8,601	1 in 2,993,148
			Micronesian Population	1 in 2	99%	1 in 101	1 in 808
<i>CNTNAP2</i>	Cortical dysplasia-focal epilepsy syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COASY</i>	Pontocerebellar hypoplasia type 12	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COL11A2</i>	Otospondylomegalaphyseal dysplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COL11A2</i>	Fibrochondrogenesis 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COL11A2</i>	Nonsyndromic hearing loss 53	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COL17A1</i>	Junctional epidermolysis bullosa	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COL27A1</i>	Steel syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>COL4A3</i>	Alport syndrome, COL4A3-related	AR	General Population	1 in 267	98%	1 in 13,301	<1 in 10 million
			Ashkenazi Jewish Population	1 in 188	98%	1 in 9,351	1 in 7,031,952
<i>COL4A4</i>	Alport syndrome, COL4A4-related	AR	General Population	1 in 267	98%	1 in 13,301	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>COL4A5</i>	Alport syndrome, COL4A5-related	XL	General Population	1 in 139	98%	1 in 6,901	1 in 27,604
<i>COL7A1</i>	Dystrophic epidermolysis bullosa	AR	General Population	1 in 196	97%	1 in 6,501	1 in 5,096,784
<i>COLQ</i>	Congenital myasthenic syndrome 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COQ4</i>	Primary Coenzyme Q10 deficiency 7	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CORO1A</i>	Immunodeficiency 8	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COX10</i>	Mitochondrial complex IV deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COX15</i>	Mitochondrial complex IV deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COX20</i>	Mitochondrial complex IV deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>COX6B1</i>	Mitochondrial complex IV deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CP</i>	Aceruloplasminemia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CPLANE1</i>	Joubert syndrome 17	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CPS1</i>	Carbamoylphosphate synthetase I deficiency	AR	General Population	1 in 570	98%	1 in 28,451	<1 in 10 million
<i>CPT1A</i>	Carnitine palmitoyltransferase IA deficiency	AR	General Population	1 in 354	90%	1 in 3,531	1 in 4,999,896
			Hutterite Population	1 in 16	90%	1 in 151	1 in 9,664
<i>CPT2</i>	Carnitine palmitoyltransferase II deficiency	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			Ashkenazi Jewish Population	1 in 51	95%	1 in 1,001	1 in 204,204
<i>CRADD</i>	Intellectual developmental disorder with variant lissencephaly	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
			Bukharian Jewish Population	1 in 30	99%	1 in 2,901	1 in 348,120
<i>CRB1</i>	Leber congenital amaurosis 8	AR	General Population	1 in 104	98%	1 in 5,151	1 in 2,142,816
<i>CRB1</i>	Retinitis pigmentosa 12	AR	General Population	1 in 104	98%	1 in 5,151	1 in 2,142,816
<i>CRLF1</i>	Crisponi cold-induced sweating syndrome 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CRTAP</i>	Osteogenesis imperfecta, type VII	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CRYL1</i>	GJB6-CRYL1 related nonsyndromic hearing loss	UK	General Population	1 in 423	99%	1 in 42,201	<1 in 10 million
<i>CTC1</i>	Cerebroretinal microangiopathy with calcifications and cysts 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CTNS</i>	Cystinosis	AR	General Population	1 in 158	99%	1 in 15,701	1 in 9,923,032
			British Population	1 in 81	99%	1 in 8,001	1 in 2,592,324
			Moroccan Jewish Population	1 in 100	99%	1 in 9,901	1 in 3,960,400
<i>CTSA</i>	Galactosialidosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CTSC</i>	Papillon-Lefevre syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CTSD</i>	Neuronal ceroid lipofuscinosis, CTSD-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CTSF</i>	Neuronal ceroid lipofuscinosis 13	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CTSK</i>	Pycnodysostosis	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CUL4B</i>	X-linked intellectual disability, CUL4B-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>CUL7</i>	Three M syndrome 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CWC27</i>	Retinitis pigmentosa with or without skeletal anomalies	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CYBA</i>	Chronic granulomatous disease	AR	General Population	1 in 224	99%	1 in 22,301	<1 in 10 million
<i>CYBB</i>	Chronic granulomatous disease, X-linked	XL	General Population	1 in 149,254	99%	1 in 14,925,301	<1 in 10 million
<i>CYP11A1</i>	Congenital adrenal insufficiency	AR	General Population	1 in 114	99%	1 in 11,301	1 in 5,153,256
<i>CYP11B1</i>	Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency	AR	General Population	1 in 158	98%	1 in 7,851	1 in 4,961,832
			Moroccan Jewish Population	1 in 35	98%	1 in 1,701	1 in 238,140
<i>CYP11B2</i>	Corticosterone methyl oxidase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CYP17A1</i>	Congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CYP19A1</i>	Aromatase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>CYP1B1</i>	Primary congenital glaucoma	AR	General Population	1 in 50	99%	1 in 4,901	1 in 980,200
<i>CYP21A2</i>	Congenital adrenal hyperplasia due to 21-hydroxylase deficiency	AR	General Population	1 in 61	99%	1 in 6,001	1 in 1,464,244
			Inuit Population	1 in 9	99%	1 in 801	1 in 28,836
			Middle-Eastern Population	1 in 35	99%	1 in 3,401	1 in 476,140
<i>CYP27A1</i>	Cerebrotendinous xanthomatosis	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Moroccan Jewish Population	1 in 5	98%	1 in 201	1 in 4,020
<i>CYP27B1</i>	Vitamin D-dependent rickets, type 1	AR	General Population	1 in 181	99%	1 in 18,001	1 in 13,032,724
<i>CYP4F22</i>	Congenital ichthyosis 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>CYP7B1</i>	Congenital bile acid synthesis defect 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DBT</i>	Maple syrup urine disease, type II	AR	General Population	1 in 481	98%	1 in 24,001	<1 in 10 million
<i>DCAF17</i>	Woodhouse-Sakati syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DCLRE1C</i>	Severe combined immunodeficiency with sensitivity to ionizing radiation	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>DCX</i>	Lissencephaly, X-linked	XL	General Population	1 in 42,500	98%	1 in 2,124,951	1 in 8,499,904
<i>DDB2</i>	Xeroderma pigmentosum, group E	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DDC</i>	Aromatic l-amino acid decarboxylase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DDR2</i>	Spondylometaepiphyseal dysplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DDX11</i>	Warsaw breakage syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 68	99%	1 in 6,701	1 in 1,822,672
<i>DGUOK</i>	Mitochondrial DNA depletion syndrome 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DHCR24</i>	Desmosterolosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DHCR7</i>	Smith-Lemli-Opitz syndrome	AR	General Population	1 in 30	96%	1 in 726	1 in 87,120
			African/African American Population	1 in 138	96%	1 in 3,426	1 in 1,891,152
			Ashkenazi Jewish Population	1 in 36	96%	1 in 876	1 in 126,144
<i>DHDDS</i>	Retinitis pigmentosa 59	AR	General Population	1 in 296	98%	1 in 14,751	<1 in 10 million
			Ashkenazi Jewish Population	1 in 118	98%	1 in 5,851	1 in 2,761,672
<i>DKC1</i>	X-linked dyskeratosis congenita	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>DLAT</i>	Pyruvate dehydrogenase E2 deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DLD</i>	Dihydropolipoamide dehydrogenase deficiency	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 107	98%	1 in 5,301	1 in 2,268,828
<i>DLG3</i>	X-linked intellectual disability, DLG3-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>DLL3</i>	Spondylocostal dysostosis 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DMD</i>	Duchenne Muscular Dystrophy	XL	General Population	1 in 2,350	93%	1 in 33,558	1 in 134,260
<i>DMD</i>	Becker Muscular Dystrophy	XL	General Population	1 in 2,350	93%	1 in 33,558	1 in 134,260
<i>DNAH5</i>	Primary ciliary dyskinesia, DNAH5-related	AR	General Population	1 in 142	98%	1 in 7,051	1 in 4,004,968
			Ashkenazi Jewish Population	1 in 113	99%	1 in 11,201	1 in 5,062,852
<i>DNAI1</i>	Primary ciliary dyskinesia, DNAI1-related	AR	General Population	1 in 230	98%	1 in 11,451	<1 in 10 million
<i>DNAI2</i>	Primary ciliary dyskinesia, DNAI2-related	AR	General Population	1 in 447	98%	1 in 22,301	<1 in 10 million
<i>DNAL1</i>	Primary ciliary dyskinesia, DNAL1-related	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>DNMT3B</i>	ICF Syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DOCK8</i>	Hyper-IgE syndrome due to DOCK8 deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DOK7</i>	Congenital myasthenic syndrome, DOK7-related	AR	General Population	1 in 472	98%	1 in 23,551	<1 in 10 million
<i>DPYD</i>	Dihydropyrimidine dehydrogenase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>DTNBP1</i>	Hermansky-Pudlak syndrome 7	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DUOX2</i>	Congenital hypothyroidism, DUOX2-related	AR	General Population	1 in 366	91%	1 in 4,057	1 in 5,938,797
<i>DUOXA2</i>	Congenital hypothyroidism, DUOXA2-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>DYNC2H1</i>	Short-rib thoracic dysplasia 3 with or without polydactyly	AR	General Population	1 in 68	98%	1 in 3,351	1 in 924,876
<i>DYSF</i>	Limb-girdle muscular dystrophy type 2B	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			Japanese Population	1 in 332	95%	1 in 6,621	1 in 8,792,688
			Libyan Jewish Population	1 in 18	95%	1 in 341	1 in 24,552
<i>EDA</i>	Hypohidrotic ectodermal dysplasia	XL	General Population	1 in 14,167	99%	1 in 1,416,601	1 in 5,666,472
<i>EIF2AK3</i>	Wolcott-Rallison Syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>EIF2B1</i>	Leukoencephalopathy with vanishing white matter	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>EIF2B2</i>	Leukoencephalopathy with vanishing white matter	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>EIF2B3</i>	Leukoencephalopathy with vanishing white matter	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>EIF2B4</i>	Leukoencephalopathy with vanishing white matter	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>EIF2B5</i>	Leukoencephalopathy with vanishing white matter	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ELP1</i>	Familial Dysautonomia	AR	General Population	1 in 300	99%	1 in 29,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 31	99%	1 in 3,001	1 in 372,124
<i>EMD</i>	Emery-Dreifuss muscular dystrophy	XL	General Population	1 in 81,967	99%	1 in 8,196,601	<1 in 10 million
<i>EPB42</i>	Spherocytosis, type 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ERBB3</i>	Lethal congenital contractural syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ERCC2</i>	Xeroderma pigmentosum, group D	AR	General Population	1 in 65	99%	1 in 6,401	1 in 1,664,260
<i>ERCC2</i>	Photosensitive trichothiodystrophy 1	AR	General Population	1 in 65	99%	1 in 6,401	1 in 1,664,260
<i>ERCC2</i>	Cerebrooculofacioskeletal syndrome 2	AR	General Population	1 in 65	99%	1 in 6,401	1 in 1,664,260

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>ERCC3</i>	Xeroderma pigmentosum, complementation group B	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ERCC3</i>	Photosensitive Trichothiodystrophy 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ERCC4</i>	Fanconi anemia, complementation group Q	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ERCC4</i>	Xeroderma pigmentosum, complementation group F	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ERCC5</i>	Xeroderma Pigmentosa, group G	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ERCC6</i>	De Sanctis-Cacchione syndrome	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
			Japanese Population	1 in 74	99%	1 in 7,301	1 in 2,161,096
<i>ERCC6</i>	Cockayne syndrome type B	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
			Japanese Population	1 in 74	99%	1 in 7,301	1 in 2,161,096
<i>ERCC8</i>	Cockayne syndrome type A	AR	General Population	1 in 822	98%	1 in 41,051	<1 in 10 million
<i>ESCO2</i>	Roberts syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ETFA</i>	Glutaric aciduria IIA	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>ETFB</i>	Glutaric aciduria IIB	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>ETFDH</i>	Glutaric aciduria IIC	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
			East Asian Population	1 in 74	98%	1 in 3,651	1 in 1,080,696
<i>ETHE1</i>	Ethylmalonic encephalopathy	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>EVC</i>	Weyers acrofacial dysostosis, EVC-related	AR	General Population	1 in 142	98%	1 in 7,051	1 in 4,004,968
			Amish Population	1 in 7	98%	1 in 301	1 in 8,428
<i>EVC</i>	Ellis-van Creveld syndrome, EVC-related	AR	General Population	1 in 142	98%	1 in 7,051	1 in 4,004,968
			Amish Population	1 in 7	98%	1 in 301	1 in 8,428
<i>EVC2</i>	Weyers acrofacial dysostosis, EVC2-related	AR	General Population	1 in 240	98%	1 in 11,951	<1 in 10 million
			Amish Population	1 in 7	98%	1 in 301	1 in 8,428
<i>EVC2</i>	Ellis-van Creveld syndrome, EVC2-related	AR	General Population	1 in 240	98%	1 in 11,951	<1 in 10 million
			Amish Population	1 in 7	98%	1 in 301	1 in 8,428
<i>EXOSC3</i>	Pontocerebellar hypoplasia type 1B	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>EYS</i>	Retinitis pigmentosa 25	AR	General Population	1 in 66	98%	1 in 3,251	1 in 858,264
<i>F11</i>	Factor XI deficiency	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 11	98%	1 in 501	1 in 22,044
<i>F2</i>	Prothrombin-related conditions	AR	General Population	1 in 33	99%	1 in 3,201	1 in 422,532
			Caucasian / European Population	1 in 4	99%	1 in 301	1 in 4,816
<i>F5</i>	Factor V deficiency	AR	General Population	1 in 36	99%	1 in 3,501	1 in 504,144
			Caucasian / European Population	1 in 19	99%	1 in 1,801	1 in 136,876
			Latino Population	1 in 45	99%	1 in 4,401	1 in 792,180
			African/African American Population	1 in 83	99%	1 in 8,201	1 in 2,722,732
			East Asian Population	1 in 222	99%	1 in 22,101	<1 in 10 million
			Native American Population	1 in 80	99%	1 in 7,901	1 in 2,528,320
<i>F7</i>	Factor VII deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>F8</i>	Hemophilia A	XL	General Population	1 in 3,250	48%	1 in 6,249	1 in 25,000
<i>F9</i>	Hemophilia B	XL	General Population	1 in 15,000	99%	1 in 1,499,901	1 in 5,999,804
<i>FA2H</i>	Spastic paraplegia type 35	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FAH</i>	Tyrosinemia, type 1	AR	General Population	1 in 99	95%	1 in 1,961	1 in 776,556
			Ashkenazi Jewish Population	1 in 150	95%	1 in 2,981	1 in 1,788,600
			Finnish Population	1 in 122	95%	1 in 2,421	1 in 1,181,448
			French Canadian Population	1 in 66	95%	1 in 1,301	1 in 343,464
			South Asian/Indian Population	1 in 172	95%	1 in 3,421	1 in 2,353,648
<i>FAM126A</i>	Hypomyelinating leukodystrophy type 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FAM126A</i>	Hypomyelinating leukodystrophy type 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FAM161A</i>	Retinitis pigmentosa 28	AR	General Population	1 in 296	98%	1 in 14,751	<1 in 10 million
<i>FANCA</i>	Fanconi anemia group A	AR	General Population	1 in 239	99%	1 in 23,801	<1 in 10 million
			Moroccan Jewish	1 in 100	99%	1 in 9,901	1 in 3,960,400
			Indian Jewish Population	1 in 27	99%	1 in 2,601	1 in 280,908
<i>FANCB</i>	Fanconi anemia group B	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>FANCC</i>	Fanconi anemia group C	AR	General Population	1 in 535	99%	1 in 53,401	<1 in 10 million
			Ashkenazi Jewish Population	1 in 99	99%	1 in 9,801	1 in 3,881,196
<i>FANCD2</i>	Fanconi anemia, group D2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FANCE</i>	Fanconi anemia, group E	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FANCF</i>	Fanconi anemia, group F	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FANCG</i>	Fanconi anemia group G	AR	General Population	1 in 632	90%	1 in 6,311	<1 in 10 million
<i>FANCI</i>	Fanconi anemia, group I	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FANCL</i>	Fanconi anemia, group L	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>FBP1</i>	Fructose-1,6-bisphosphatase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FBXL4</i>	Mitochondrial DNA depletion syndrome 13	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FGD1</i>	X-linked Aarskog-Scott syndrome	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>FH</i>	Fumarase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 99	99%	1 in 9,801	1 in 3,881,196
<i>FHL1</i>	Emery-Dreifuss muscular dystrophy 6	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>FHL1</i>	X-linked myopathy with postural muscle atrophy	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>FKRP</i>	Muscular dystrophy-dystroglycanopathy, FKRP-related	AR	General Population	1 in 158	98%	1 in 7,851	1 in 4,961,832
<i>FKTN</i>	Muscular dystrophy-dystroglycanopathy, FKTN-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 150	99%	1 in 14,901	1 in 8,940,600
			Japanese Population	1 in 82	99%	1 in 8,101	1 in 2,657,128
<i>FKTN</i>	Fukuyama congenital muscular dystrophy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 150	99%	1 in 14,901	1 in 8,940,600
			Japanese Population	1 in 82	99%	1 in 8,101	1 in 2,657,128
<i>FMO3</i>	Trimethylaminuria	AR	General Population	1 in 139	99%	1 in 13,801	1 in 7,763,356
<i>FMR1</i>	Fragile X Syndrome Intermediate Allele	XL	General Population	1 in 259	99%	1 in 25,801	1 in 103,204
			Ashkenazi Jewish Population	1 in 115	99%	1 in 11,401	1 in 45,604
<i>FMR1</i>	Fragile X Syndrome Premutation	XL	General Population	1 in 259	99%	1 in 25,801	1 in 103,204
			Ashkenazi Jewish Population	1 in 115	99%	1 in 11,401	1 in 45,604
<i>FMR1</i>	Fragile X Syndrome Full Mutation	XL	General Population	1 in 11,111	99%	1 in 1,111,001	1 in 4,444,004
<i>FOLR1</i>	Cerebral folate deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FOXN1</i>	T-cell immunodeficiency with congenital alopecia and nail dystrophy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FOXN1</i>	T-cell immunodeficiency with thymic aplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FOXP3</i>	IPEX syndrome	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>FOXRED1</i>	Mitochondrial complex I deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FRAS1</i>	Fraser syndrome	AR	General Population	1 in 250	99%	1 in 24,901	<1 in 10 million
<i>FREM2</i>	Fraser syndrome	AR	General Population	1 in 354	99%	1 in 35,301	<1 in 10 million
<i>FTCD</i>	Glutamate formiminotransferase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FTSJ1</i>	X-linked intellectual disability, FTSJ1-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>FUCA1</i>	Fucosidosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>FXN</i>	Friedreich ataxia	AR	General Population	1 in 80	4%	1 in 83	1 in 26,653
			Caucasian / European Population	1 in 80	98%	1 in 3951	1 in 1,264,320
<i>G6PC</i>	Glycogen storage disease, type 1a	AR	General Population	1 in 177	95%	1 in 3,521	1 in 2,492,868
			Ashkenazi Jewish Population	1 in 64	95%	1 in 1,261	1 in 322,816
<i>G6PC3</i>	Severe congenital neutropenia 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>G6PD</i>	Glucose-6-phosphate dehydrogenase deficiency	XL	General Population	1 in 7	98%	1 in 301	1 in 1,204
<i>GAA</i>	Pompe disease	AR	General Population	1 in 100	98%	1 in 4,951	1 in 1,980,400
			African/African American Population	1 in 60	98%	1 in 2,951	1 in 708,240
			East Asian Population	1 in 112	98%	1 in 5,551	1 in 2,486,848
			Ashkenazi Jewish Population	1 in 76	99%	1 in 7,501	1 in 2,280,304
<i>GALC</i>	Krabbe disease	AR	General Population	1 in 158	99%	1 in 15,701	1 in 9,923,032
			Israeli Druze Population	1 in 6	99%	1 in 501	1 in 12,024
<i>GALE</i>	Galactose epimerase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>GALK1</i>	Galactokinase deficiency	AR	General Population	1 in 110	95%	1 in 2,181	1 in 959,640
			Irish Population	1 in 64	95%	1 in 1,261	1 in 322,816
<i>GALNS</i>	Mucopolysaccharidosis IVA (Morquio syndrome A)	AR	General Population	1 in 224	97%	1 in 7,434	1 in 6,660,864
<i>GALNT3</i>	Familial hyperphosphatemic tumoral calcinosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>GALT</i>	Galactosemia	AR	General Population	1 in 110	99%	1 in 10,901	1 in 4,796,440
			African/African American Population	1 in 94	99%	1 in 9,301	1 in 3,497,176
			Ashkenazi Jewish Population	1 in 127	99%	1 in 12,601	1 in 6,401,308
<i>GAMT</i>	Guanidinoacetate methyltransferase deficiency	AR	General Population	1 in 371	99%	1 in 37,001	<1 in 10 million
<i>GBA</i>	Gaucher disease	AR	General Population	1 in 77	99%	1 in 7,601	1 in 2,341,108
			African/African American Population	1 in 35	99%	1 in 3,401	1 in 476,140
			Ashkenazi Jewish Population	1 in 15	99%	1 in 1,401	1 in 84,060
<i>GBE1</i>	Glycogen storage disease IV	AR	General Population	1 in 387	99%	1 in 38,601	<1 in 10 million



# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
GCDH	Glutaric aciduria, type I	AR	General Population	1 in 87	98%	1 in 4,301	1 in 1,496,748
			Amish Population	1 in 9	98%	1 in 401	1 in 14,436
GDAP1	Charcot-Marie-Tooth disease, GDAP1-related	AR	General Population	1 in 152	99%	1 in 15,101	1 in 9,181,408
GDF5	Du Pan Syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
GFM1	Combined oxidative phosphorylation deficiency, GFM1-related	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
GFPT1	Congenital myasthenic syndrome 12	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
GHR	Growth hormone insensitivity syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
GHRHR	Isolated growth hormone deficiency, type 1B	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
GJB1	Charcot-Marie-Tooth disease, X-linked type 1	XL	General Population	1 in 667	90%	1 in 6,661	1 in 26,644
GJB2	Nonsyndromic hearing loss 1A	AR	General Population	1 in 42	99%	1 in 4,101	1 in 688,968
			African/African American Population	1 in 25	99%	1 in 2,401	1 in 140,100
			Ashkenazi Jewish Population	1 in 21	99%	1 in 2,001	1 in 168,084
			Caucasian / European Population	1 in 33	99%	1 in 3,201	1 in 422,532
			Latino Population	1 in 100	99%	1 in 9,901	1 in 3,960,400
			Middle-Eastern Population	1 in 83	99%	1 in 8,201	1 in 2,722,732
			South Asian/Indian Population	1 in 148	99%	1 in 14,701	1 in 8,702,992
GJB6	GJB6-CRYL1 related nonsyndromic hearing loss	AR	General Population	1 in 423	99%	1 in 42,201	<1 in 10 million
GLA	Fabry disease	XL	General Population	1 in 25,000	99%	1 in 2,499,901	1 in 9,999,804
GLB1	GM1-gangliosidosis	AR	General Population	1 in 134	99%	1 in 13,301	1 in 7,129,336
			Maltese Population	1 in 30	99%	1 in 2,901	1 in 348,120
			Roma Population	1 in 50	99%	1 in 4,901	1 in 980,200
GLB1	Mucopolysaccharidosis type IVB (Morquio syndrome B)	AR	General Population	1 in 134	99%	1 in 13,301	1 in 7,129,336
			Maltese Population	1 in 30	99%	1 in 2,901	1 in 348,120
			Roma Population	1 in 50	99%	1 in 4,901	1 in 980,200
GLDC	Glycine encephalopathy, GLDC-related	AR	General Population	1 in 193	98%	1 in 9,601	1 in 7,411,972
			British Columbia Canadian Population	1 in 125	99%	1 in 12,401	1 in 6,200,500
			Finnish Population	1 in 117	99%	1 in 11,601	1 in 5,429,268
GLE1	Lethal congenital contracture syndrome 1	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Finnish Population	1 in 80	98%	1 in 3,951	1 in 1,264,320
GNE	Inclusion body myopathy type 2 (Nonaka myopathy)	AR	General Population	<1 in 500	99%	1 in 49,901	1 in 99,802,000
			Iranian Jewish Population	1 in 11	99%	1 in 1,001	1 in 44,044
GNPAT	Rhizomelic chondrodysplasia punctata, type 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
GNPTAB	Mucopolipidosis II alpha/beta	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
GNPTAB	Mucopolipidosis III alpha/beta	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
GNPTG	Mucopolipidosis III gamma	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
GNRHR	Hypogonadotropic hypogonadism, GNRHR-related	AR	General Population	1 in 347	99%	1 in 34,601	<1 in 10 million
GNS	Mucopolysaccharidosis IIID (Sanfilippo syndrome D)	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
GORAB	Geroderma osteodysplasticum	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
GP1BA	Bernard-Soulier syndrome type A1	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
GP9	Bernard-Soulier syndrome type C	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
GPR143	X-linked Ocular albinism, GPR143-related	XL	General Population	1 in 25,000	99%	1 in 2,499,901	<1 in 10 million
GRHPR	Primary hyperoxaluria type II	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
GRIP1	Fraser syndrome	AR	General Population	1 in 84	99%	1 in 8,301	1 in 2,789,136
GSS	Glutathione synthetase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
GUCY2D	Leber congenital amaurosis 1	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
GUSB	Mucopolysaccharidosis type VII	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
GYS2	Glycogen storage disease, type 0, liver	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
HADH	Familial hyperinsulinemic hypoglycemia 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
HADHA	Trifunctional protein deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Finnish Population	1 in 124	98%	1 in 6,151	1 in 3,050,896
HADHA	Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Finnish Population	1 in 124	98%	1 in 6,151	1 in 3,050,896
HADHB	Trifunctional protein deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Finnish Population	1 in 124	98%	1 in 6,151	1 in 3,050,896
HAMP	Hemochromatosis, type 2B	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
HAX1	Severe congenital neutropenia, HAX1-related	AR	General Population	1 in 224	98%	1 in 11,151	1 in 9,991,296

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>HBA1</i>	Alpha thalassemia	AR	General Population	1 in 1000	98%	1 in 860	1 in 3,440,364
			General Population†	1 in 18	98%	1 in 860	1 in 3,440,364
			Southeast Asian Population	≤1 in 7	98%	≤1 in 305	≤1 in 17,228
			Southeast Asian Population†	≤1 in 14	98%	≤1 in 305	≤1 in 17,228
			Mediterranean Population	≤1 in 6	98%	≤1 in 229	≤1 in 457,556
			Mediterranean Population†	1 in 500	98%	≤1 in 229	≤1 in 457,556
			African/African American Population	1 in 30	98%	1 in 1,451	1 in 5,804,000
<i>HBA2</i>	Alpha thalassemia	AR	General Population	1 in 1000	98%	1 in 860	1 in 3,440,364
			General Population†	1 in 18	98%	1 in 860	1 in 3,440,364
			Southeast Asian Population	≤1 in 7	98%	≤1 in 305	≤1 in 17,228
			Southeast Asian Population†	≤1 in 14	98%	≤1 in 305	≤1 in 17,228
			Mediterranean Population	≤1 in 6	98%	≤1 in 229	≤1 in 457,556
			Mediterranean Population†	1 in 500	98%	≤1 in 229	≤1 in 457,556
			African/African American Population	1 in 30	98%	1 in 1,451	1 in 5,804,000
<i>HBB</i>	Sickle cell disease	AR	General Population	1 in 158	95%	1 in 3,141	1 in 1,985,112
			African/African American Population	1 in 10	95%	1 in 181	1 in 7,240
			East Asian Population	1 in 50	95%	1 in 981	1 in 196,200
			Latino Population	1 in 128	95%	1 in 2,541	1 in 1,300,992
			Mediterranean Population	1 in 3	95%	1 in 41	1 in 492
			South Asian/Indian Population	1 in 25	95%	1 in 481	1 in 48,100
<i>HBB</i>	Hemoglobin C disease	AR	General Population	1 in 158	95%	1 in 3,141	1 in 1,985,112
			African/African American Population	1 in 10	95%	1 in 181	1 in 7,240
			East Asian Population	1 in 50	95%	1 in 981	1 in 196,200
			Latino Population	1 in 128	95%	1 in 2,541	1 in 1,300,992
			Mediterranean Population	1 in 3	95%	1 in 41	1 in 492
			South Asian/Indian Population	1 in 25	95%	1 in 481	1 in 48,100
<i>HBB</i>	Beta thalassemia	AR	General Population	1 in 158	95%	1 in 3,141	1 in 1,985,112
			African/African American Population	1 in 10	95%	1 in 181	1 in 7,240
			East Asian Population	1 in 50	95%	1 in 981	1 in 196,200
			Latino Population	1 in 128	95%	1 in 2,541	1 in 1,300,992
			Mediterranean Population	1 in 3	95%	1 in 41	1 in 492
			South Asian/Indian Population	1 in 25	95%	1 in 481	1 in 48,100
<i>HCFC1</i>	Methylmalonic acidemia with homocystinuria, type cblX	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>HELLS</i>	Immunodeficiency, Centromeric region instability, Facial anomalies syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HEXA</i>	Tay-Sachs disease	AR	General Population	1 in 300	99%	1 in 29,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 27	99%	1 in 2,601	1 in 280,908
			Moroccan Jewish Population	1 in 110	99%	1 in 10,901	1 in 4,796,440
<i>HEXB</i>	Sandhoff disease	AR	General Population	1 in 600	98%	1 in 29,951	<1 in 10 million
<i>HFE</i>	Hereditary Hemochromatosis	AR	General Population	1 in 10	99%	1 in 901	1 in 36,040
			African/African American Population	1 in 17	99%	1 in 1,601	1 in 108,868
			Caucasian / European Population	1 in 3	99%	1 in 201	1 in 2,412
			East Asian Population	1 in 12	99%	1 in 1,101	1 in 52,848
			Latino Population	1 in 6	99%	1 in 501	1 in 12,024
<i>HGD</i>	Alkaptonuria	AR	General Population	1 in 250	90%	1 in 2,491	1 in 2,491,000
<i>HGSNAT</i>	Mucopolysaccharidosis type IIIC (Sanfilippo syndrome C)	AR	General Population	1 in 434	98%	1 in 21,651	<1 in 10 million
			Caucasian / European Population	1 in 345	98%	1 in 17,201	<1 in 10 million
<i>HINT1</i>	Neuromyotonia and axonal neuropathy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HJV</i>	Hemochromatosis, type 2A	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HLCS</i>	Holocarboxylase synthetase deficiency	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>HMGL</i>	3-hydroxy-3-methylglutaryl-CoA lyase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>HMGS2</i>	3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HOGA1</i>	Primary hyperoxaluria type III	AR	General Population	1 in 184	99%	1 in 18,301	<1 in 10 million
<i>HPD</i>	Tyrosinemia type III	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HPS1</i>	Hermansky-Pudlak syndrome 1	AR	General Population	1 in 354	98%	1 in 17,651	<1 in 10 million
			Puerto Rican Population	1 in 21	98%	1 in 1,001	1 in 84,084
<i>HPS3</i>	Hermansky-Pudlak syndrome 3	AR	General Population	1 in 354	98%	1 in 17,651	<1 in 10 million
<i>HPS4</i>	Hermansky-Pudlak syndrome 4	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>HPS5</i>	Hermansky-Pudlak syndrome 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HPS6</i>	Hermansky-Pudlak syndrome 6	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HSD17B10</i>	HSD10 mitochondrial disease	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>HSD17B3</i>	17-Beta-Hydroxysteroid Dehydrogenase Deficiency	AR	General Population	1 in 192	98%	1 in 9,551	1 in 7,335,168
			Palestinian Population	1 in 8	98%	1 in 351	1 in 11,232
<i>HSD17B4</i>	D-bifunctional protein deficiency	AR	General Population	1 in 158	98%	1 in 7,851	1 in 4,961,832
<i>HSD3B2</i>	Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>HSD3B7</i>	Congenital bile acid synthesis defect	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>HYAL1</i>	Mucopolysaccharidosis type IX	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>HYLS1</i>	Hydrolethalus syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Finnish Population	1 in 50	98%	1 in 2,451	1 in 490,200
<i>IDH3B</i>	Retinitis pigmentosa, IDH3B-related	AR	General Population	1 in 296	99%	1 in 29,501	<1 in 10 million
<i>IDS</i>	Mucopolysaccharidosis type II (Hunter syndrome)	XL	General Population	1 in 50,000	91%	1 in 555,545	1 in 2,222,204
<i>IDUA</i>	Mucopolysaccharidosis, type I (Hurler syndrome)	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			Caucasian / European Population	1 in 153	95%	1 in 3,041	1 in 1,861,092
<i>IFT140</i>	Mainzer-Saldino syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>IFT140</i>	Asphyxiating thoracic dystrophy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>IGHMBP2</i>	Charcot-Marie-Tooth disease type 2S	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>IGHMBP2</i>	Spinal muscular atrophy with respiratory distress 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>IGSF1</i>	X-linked central hypothyroidism and testicular enlargement	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>IKBKB</i>	Immunodeficiency 15B	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>IL1RAPL1</i>	X-linked intellectual disability, IL1RAPL1-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>IL2RA</i>	Immunodeficiency due to CD25 deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>IL2RG</i>	Severe combined immunodeficiency, X-linked	XL	General Population	1 in 25,000	99%	1 in 2,499,901	1 in 9,999,804
<i>IL7R</i>	Severe Combined Immunodeficiency 104	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>INPP5E</i>	Joubert syndrome 1	AR	General Population	1 in 159	99%	1 in 15,801	<1 in 10 million
<i>INVS</i>	Nephronophthisis 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ITGA2B</i>	Glanzmann thrombasthenia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ITGA6</i>	Junctional epidermolysis bullosa	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ITGB3</i>	Glanzmann thrombasthenia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ITGB4</i>	Junctional epidermolysis bullosa	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ITPA</i>	Developmental and epileptic encephalopathy 35	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>IVD</i>	Isovaleric Acidemia	AR	General Population	1 in 167	90%	1 in 1,661	1 in 1,109,548
			African/African American Population	1 in 100	90%	1 in 991	1 in 396,400
			Caucasian / European Population	1 in 115	90%	1 in 1,141	1 in 524,860
			East Asian Population	1 in 407	90%	1 in 4,061	1 in 6,611,308
<i>IYD</i>	Thyroid dysmorphogenesis, IYD-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>JAK3</i>	Severe combined immunodeficiency, JAK3-related	AR	General Population	1 in 299	99%	1 in 29,801	<1 in 10 million
<i>KCNJ1</i>	Bartter syndrome	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>KCNJ1</i>	Bartter syndrome type 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>KCNJ11</i>	Congenital hyperinsulinism	AR	General Population	1 in 423	99%	1 in 42,201	<1 in 10 million
			Caucasian / European Population	1 in 232	99%	1 in 23,101	<1 in 10 million
<i>KCNJ11</i>	Permanent neonatal diabetes mellitus	AR	General Population	1 in 423	99%	1 in 42,201	<1 in 10 million
			Caucasian / European Population	1 in 232	99%	1 in 23,101	<1 in 10 million
<i>KCTD7</i>	Progressive myoclonic epilepsy type 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>KDM5C</i>	X-linked intellectual disability, KDM5C-related	XL	General Population	<1 in 50,000	98%	1 in 2,499,951	<1 in 10 million
<i>KIF14</i>	Primary Autosomal Recessive Microcephaly 20	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>L1CAM</i>	L1 syndrome	XL	General Population	1 in 15,000	99%	1 in 1,499,901	1 in 5,999,804
<i>LAMA2</i>	Muscular dystrophy, LAMA2-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Caucasian / European Population	1 in 125	99%	1 in 12,401	1 in 6,200,500
<i>LAMA3</i>	Junctional epidermolysis bullosa, LAMA3-related	AR	General Population	1 in 781	98%	1 in 39,001	<1 in 10 million
<i>LAMA3</i>	Laryngo-onycho-cutaneous syndrome	AR	General Population	1 in 781	98%	1 in 39,001	<1 in 10 million
<i>LAMB3</i>	Junctional epidermolysis bullosa, LAMB3-related	AR	General Population	1 in 781	98%	1 in 39,001	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>LAMC2</i>	Junctional epidermolysis bullosa, LAMC2-related	AR	General Population	1 in 781	98%	1 in 39,001	<1 in 10 million
<i>LARS</i>	Infantile liver failure syndrome 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LCA5</i>	Leber congenital amaurosis 5	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>LCK</i>	Immunodeficiency 22	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LDLR</i>	Familial Hypercholesterolemia	AD	General Population	1 in 8	99%	1 in 701	1 in 22,432
			Amish Population	1 in 2	99%	1 in 101	1 in 808
			Caucasian / European Population	1 in 7	99%	1 in 601	1 in 16,828
			French Canadian Population	1 in 8	99%	1 in 701	1 in 22,432
<i>LDLR</i>	Familial hypercholesterolemia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LDLRAP1</i>	Familial Hypercholesterolemia	AR	General Population	1 in 8	99%	1 in 701	1 in 22,432
			Amish Population	1 in 2	99%	1 in 101	1 in 808
			Caucasian / European Population	1 in 7	99%	1 in 601	1 in 16,828
			French Canadian Population	1 in 8	99%	1 in 701	1 in 22,432
<i>LHCGR</i>	Leydig cell hypoplasia	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>LHX3</i>	Combined pituitary hormone deficiency 3	AR	General Population	1 in 45	98%	1 in 2,201	1 in 396,180
<i>LIFR</i>	Stuve-Wiedemann syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>LIG4</i>	LIG4 syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LIG4</i>	Severe combined immunodeficiency with sensitivity to ionizing radiation	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LIPA</i>	Lysosomal acid lipase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Caucasian / European Population	1 in 112	99%	1 in 11,101	1 in 4,973,248
			Iranian Jewish Population	1 in 26	99%	1 in 2,501	1 in 260,104
<i>LIPN</i>	Congenital Ichthyosis 8	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LMAN1</i>	Combined factor V and VIII deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LMBRD1</i>	Methylmalonic aciduria and homocystinuria, cbIF type	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LOXHD1</i>	Nonsyndromic hearing loss 77	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 180	98%	1 in 8,951	1 in 6,444,720
<i>LPAR6</i>	Hypotrichosis 8	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LPL</i>	Familial lipoprotein lipase deficiency	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
			French Canadian Population	1 in 46	99%	1 in 4,501	1 in 828,184
<i>LRAT</i>	Leber congenital amaurosis 14	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LRP2</i>	Donnai-Barrow syndrome	AR	General Population	1 in 214	99%	1 in 10,651	1 in 9,117,256
<i>LRPPRC</i>	Leigh syndrome with Complex IV deficiency	AR	General Population	1 in 447	98%	1 in 22,301	<1 in 10 million
			Faroese Population	1 in 21	98%	1 in 1,001	1 in 84,084
			French Canadian Population	1 in 22	98%	1 in 1,051	1 in 92,488
<i>LTBP4</i>	Cutis laxa with severe pulmonary, gastrointestinal, and urinary abnormalities	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>LYST</i>	Chediak-Higashi syndrome	AR	General Population	<1 in 500	90%	1 in 4,991	1 in 9,982,000
<i>MAK</i>	Retinitis Pigmentosa 62	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MALT1</i>	Immunodeficiency 12	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MAN2B1</i>	Alpha-Mannosidosis	AR	General Population	1 in 354	99%	1 in 35,301	<1 in 10 million
			Caucasian / European Population	1 in 274	99%	1 in 27,301	<1 in 10 million
<i>MANBA</i>	Beta-Mannosidosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MAT1A</i>	Methionine adenosyltransferase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MCCC1</i>	3-Methylcrotonyl-CoA carboxylase 1 deficiency (3-MCC deficiency)	AR	General Population	1 in 95	98%	1 in 4,701	1 in 1,786,380
<i>MCCC2</i>	3-Methylcrotonyl-CoA carboxylase 2 deficiency (3-MCC deficiency)	AR	General Population	1 in 95	98%	1 in 4,701	1 in 1,786,380
<i>MCEE</i>	Methylmalonyl-CoA epimerase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MCOLN1</i>	Mucopolipidosis IV	AR	General Population	1 in 300	99%	1 in 29,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 100	99%	1 in 9,901	1 in 3,960,400
<i>MCPH1</i>	Primary microcephaly 1, recessive	AR	General Population	1 in 147	99%	1 in 14,601	1 in 8,585,388
<i>MED17</i>	Postnatal Progressive Microcephaly with Seizures and Brain Atrophy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Bukharan/Kurdish Jewish Population	1 in 20	99%	1 in 1,901	1 in 152,080
<i>MEFV</i>	Familial Mediterranean fever	AR	General Population	1 in 20	99%	1 in 1,901	1 in 152,080
			Mediterranean Population	1 in 7	90%	1 in 61	1 in 1,708
<i>MEGF8</i>	Carpenter syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MESP2</i>	Spondylocostal dysostosis	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>MFSD8</i>	Neuronal ceroid lipofuscinosis, MFSD8-related	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>MID1</i>	Opitz GBBB syndrome, type I	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>MKKS</i>	Bardet-Biedl syndrome 6	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MKS1</i>	Bardet-Biedl syndrome 13	AR	General Population	1 in 260	98%	1 in 12,951	<1 in 10 million
			Finnish Population	1 in 47	98%	1 in 2,301	1 in 432,588
<i>MKS1</i>	Joubert syndrome 28	AR	General Population	1 in 260	98%	1 in 12,951	<1 in 10 million
			Finnish Population	1 in 47	98%	1 in 2,301	1 in 432,588
<i>MKS1</i>	Meckel syndrome 1	AR	General Population	1 in 260	98%	1 in 12,951	<1 in 10 million
			Finnish Population	1 in 47	98%	1 in 2,301	1 in 432,588
<i>MLC1</i>	Megalencephalic leukoencephalopathy with subcortical cysts	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Libyan Jewish Population	1 in 40	99%	1 in 3,901	1 in 624,160
<i>MLYCD</i>	Malonyl-CoA decarboxylase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>MMAA</i>	Methylmalonic aciduria, cblA type	AR	General Population	1 in 301	97%	1 in 10,001	<1 in 10 million
<i>MMAB</i>	Methylmalonic aciduria, cblB type	AR	General Population	1 in 435	98%	1 in 21,701	<1 in 10 million
<i>MMACHC</i>	Methylmalonic aciduria and homocystinuria, cblC type	AR	General Population	1 in 134	90%	1 in 1,331	1 in 713,416
<i>MMADHC</i>	Methylmalonic aciduria and homocystinuria, cblD type	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>MPI</i>	Congenital disorder of glycosylation type Ib	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>MPL</i>	Congenital amegakaryocytic thrombocytopenia	AR	General Population	1 in 102	98%	1 in 5,051	1 in 2,060,808
			Ashkenazi Jewish Population	1 in 55	98%	1 in 2,701	1 in 594,220
<i>MPV17</i>	Hepatocerebral mitochondrial DNA depletion syndrome, MPV17-related	AR	General Population	<1 in 500	96%	1 in 12,476	<1 in 10 million
			Native American Population	1 in 20	96%	1 in 476	1 in 38,080
<i>MRE11</i>	Ataxia-Telangiectasia-Like Disorder 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MTHFD1</i>	Combined immunodeficiency and megaloblastic anemia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MTHFR</i>	Homocystinuria, MTHFR-related	AR	General Population	1 in 224	98%	1 in 11,151	1 in 9,991,296
<i>MTM1</i>	Myotubular myopathy, X-linked	XL	General Population	1 in 25,000	98%	1 in 1,249,951	1 in 4,999,904
<i>MTMR2</i>	Charcot-Marie-Tooth disease, type 4B1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MTR</i>	Methylmalonic acidemia, cblG type	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MTRR</i>	Homocystinuria-megaloblastic anemia, cobalamin E type	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>MTTP</i>	Abetalipoproteinemia	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 180	98%	1 in 8,951	1 in 6,444,720
<i>MUT</i>	Methylmalonic aciduria-methylmalonyl-CoA mutase deficiency	AR	General Population	1 in 100	99%	1 in 9,901	1 in 3,960,400
<i>MVK</i>	Hyperimmunoglobulinemia D syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MVK</i>	Mevalonate kinase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>MYO15A</i>	Nonsyndromic hearing loss, MYO15A-related	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Balinese Population	1 in 6	98%	1 in 251	1 in 6,024
			Pakistani Population	1 in 77	98%	1 in 3,801	1 in 1,170,708
<i>MYO7A</i>	Usher syndrome, type 1B	AR	General Population	1 in 206	98%	1 in 10,251	1 in 8,446,824
			East Asian Population	1 in 62	98%	1 in 3,051	1 in 756,648
<i>MYO7A</i>	Non-syndromic hearing loss, MYO7A-related	AR	General Population	1 in 206	98%	1 in 10,251	1 in 8,446,824
			East Asian Population	1 in 62	98%	1 in 3,051	1 in 756,648
<i>NAGA</i>	Schindler disease types 1 and 3	AR	General Population	1 in 94	99%	1 in 9,301	1 in 3,497,176
<i>NAGLU</i>	Mucopolysaccharidosis type IIIB (Sanfilippo syndrome B)	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Caucasian / European Population	1 in 346	99%	1 in 34,501	<1 in 10 million
			East Asian Population	1 in 298	99%	1 in 29,701	<1 in 10 million
<i>NAGS</i>	N-acetylglutamate synthase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>NBAS</i>	SOPH syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>NBEAL2</i>	Gray platelet syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>NBN</i>	Nijmegen breakage syndrome	AR	General Population	1 in 158	99%	1 in 15,701	1 in 9,923,032
<i>NCF2</i>	Chronic granulomatous disease 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>NCF4</i>	Chronic granulomatous disease 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>NDP</i>	Norrie disease	XL	General Population	<1 in 50,000	98%	1 in 2,499,951	<1 in 10 million
<i>NDRG1</i>	Charcot-Marie-Tooth disease, type 4D	AR	General Population	1 in 22	98%	1 in 1,051	1 in 92,488
<i>NDUFA11</i>	Mitochondrial complex I deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>NDUFAF2</i>	Mitochondrial complex I deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>NDUFAF5</i>	Mitochondrial complex I deficiency (Leigh syndrome)	AR	General Population	1 in 447	98%	1 in 22,301	<1 in 10 million
			Ashkenazi Jewish Population	1 in 290	98%	1 in 14,451	<1 in 10 million
<i>NDUFS4</i>	Mitochondrial complex I deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
NDUFS4	Mitochondrial complex I deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Hutterite Population	1 in 27	99%	1 in 2,601	1 in 280,908
NDUFS6	Mitochondrial complex I deficiency (Leigh syndrome)	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Bukharan/Kurdish Jewish Population	1 in 24	99%	1 in 2,301	1 in 220,896
NDUFS7	Mitochondrial complex I deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NDUFV1	Mitochondrial complex I deficiency, nuclear type 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NEB	Nemaline myopathy	AR	General Population	1 in 112	98%	1 in 5,551	1 in 2,486,848
			Amish Population	1 in 11	98%	1 in 501	1 in 22,044
			Ashkenazi Jewish Population	1 in 108	98%	1 in 5,351	1 in 2,311,632
			Finnish Population	1 in 112	98%	1 in 5,551	1 in 2,486,848
NEU1	Sialidosis, type I and II	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NGLY1	Congenital disorder of deglycosylation	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NHEJ1	Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NIPAL4	Autosomal Recessive Congenital Ichthyosis 6	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NONO	X-linked intellectual disability syndrome 34	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
NPC1	Niemann-Pick disease, type C1	AR	General Population	1 in 194	90%	1 in 1,931	1 in 1,498,456
NPC2	Niemann-Pick disease, type C2	AR	General Population	1 in 194	99%	1 in 19,301	<1 in 10 million
NPHP1	Joubert syndrome 4	AR	General Population	1 in 480	98%	1 in 23,951	<1 in 10 million
			Finnish Population	1 in 124	98%	1 in 6,151	1 in 3,050,896
NPHP1	Nephronophthisis	AR	General Population	1 in 480	98%	1 in 23,951	<1 in 10 million
			Finnish Population	1 in 124	98%	1 in 6,151	1 in 3,050,896
NPHP1	NPHP1-related disorders	AR	General Population	1 in 480	98%	1 in 23,951	<1 in 10 million
			Finnish Population	1 in 124	98%	1 in 6,151	1 in 3,050,896
NPHP1	Senior-Løken syndrome 1	AR	General Population	1 in 480	98%	1 in 23,951	<1 in 10 million
			Finnish Population	1 in 124	98%	1 in 6,151	1 in 3,050,896
NPHP3	Nephronophthisis 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NPHP3	Meckel syndrome 7	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
NPHS1	Congenital nephrotic syndrome, type 1	AR	General Population	1 in 289	98%	1 in 14,401	<1 in 10 million
			Finnish Population	1 in 50	98%	1 in 2,451	1 in 490,200
NPHS2	Congenital nephrotic syndrome, type 2	AR	General Population	1 in 289	98%	1 in 14,401	<1 in 10 million
			Finnish Population	1 in 50	98%	1 in 2,451	1 in 490,200
NR0B1	Congenital adrenal hypoplasia, X-linked	XL	General Population	1 in 6,250	99%	1 in 624,901	1 in 2,499,804
NR2E3	Retinitis pigmentosa 37	AR	General Population	1 in 209	98%	1 in 10,401	1 in 8,695,236
NR2E3	Enhanced S-cone syndrome	AR	General Population	1 in 209	98%	1 in 10,401	1 in 8,695,236
NTRK1	Congenital insensitivity to pain with anhidrosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
OAT	Gyrate atrophy of choroid and retina	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
OBSL1	3M syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
OCA2	Oculocutaneous albinism type II	AR	General Population	1 in 76	99%	1 in 7,501	1 in 2,280,304
OCRL	Lowe syndrome	XL	General Population	1 in 250,000	95%	1 in 4,999,981	<1 in 10 million
OCRL	Dent disease 2	XL	General Population	1 in 250,000	95%	1 in 4,999,981	<1 in 10 million
OPA3	Costeff syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Iraqi Jewish Population	1 in 50	98%	1 in 2,451	1 in 490,200
OPHN1	X-linked intellectual disability with cerebellar hypoplasia and distinctive facial appearance	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
OTC	Ornithine transcarbamylase deficiency	XL	General Population	1 in 7,000	90%	1 in 69,991	1 in 279,984
OTOF	Nonsyndromic hearing loss, OTOF-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Spanish Population	1 in 106	99%	1 in 10,501	1 in 4,452,424
P3H1	Osteogenesis imperfecta, type VIII	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			West African Population	1 in 67	99%	1 in 6,601	1 in 1,769,068
			African American Population	1 in 250	99%	1 in 24,901	<1 in 10,000,000
PAH	Phenylalanine Hydroxylase deficiency (Phenylketonuria)	AR	General Population	1 in 93	99%	1 in 9,201	1 in 3,422,772
			Caucasian / European Population	1 in 63	99%	1 in 6,201	1 in 1,562,652
			Middle-Eastern Population	1 in 74	99%	1 in 7,301	1 in 2,161,096
			South East Asian	1 in 59	99%	1 in 5,801	1 in 1,369,036
PAK3	X-linked intellectual disability, PAK3-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
PANK2	Pantothenate kinase-associated neurodegeneration	AR	General Population	1 in 289	99%	1 in 28,801	<1 in 10 million
PC	Pyruvate carboxylase deficiency	AR	General Population	1 in 250	95%	1 in 4,981	1 in 4,981,000

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>PCBD1</i>	Tetrahydrobiopterin deficiency, PCBD1-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PCCA</i>	Propionic acidemia, PCCA-related	AR	General Population	1 in 224	96%	1 in 5,576	1 in 4,996,096
			Native American Population	1 in 85	96%	1 in 2,101	1 in 714,340
<i>PCCB</i>	Propionic acidemia, PCCB-related	AR	General Population	1 in 224	99%	1 in 22,301	<1 in 10 million
			Native American Population	1 in 85	99%	1 in 8,401	1 in 2,856,340
<i>PCDH15</i>	Non-syndromic hearing loss, PCDH15-related	AR	General Population	1 in 395	98%	1 in 19,701	1 in 78,804
			Ashkenazi Jewish Population	1 in 72	98%	1 in 3,551	1 in 14,204
<i>PCDH15</i>	Usher syndrome, type 1F	AR	General Population	1 in 395	98%	1 in 19,701	1 in 78,804
			Ashkenazi Jewish Population	1 in 72	98%	1 in 3,551	1 in 14,204
<i>PCNT</i>	Microcephalic osteodysplastic primordial dwarfism, type II	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>PDE6A</i>	Retinitis pigmentosa, PDE6A-related	AR	General Population	1 in 133	99%	1 in 13,201	1 in 7,022,932
<i>PDHA1</i>	Pyruvate dehydrogenase E1-alpha deficiency	XL	General Population	<1 in 250,000	98%	1 in 12,499,951	<1 in 10 million
<i>PDHB</i>	Pyruvate dehydrogenase E1-beta deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>PDHX</i>	Pyruvate dehydrogenase E3-binding protein deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PDP1</i>	Pyruvate dehydrogenase phosphatase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEPD</i>	Prolidase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PET100</i>	Mitochondrial complex IV deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX1</i>	Zellweger syndrome, PEX1-related	AR	General Population	1 in 147	95%	1 in 2,921	1 in 1,717,548
<i>PEX10</i>	Zellweger syndrome, PEX10-related	AR	General Population	1 in 500	95%	1 in 9,981	<1 in 10 million
			Japanese Population	1 in 354	95%	1 in 7,061	1 in 9,998,376
<i>PEX11B</i>	Zellweger spectrum disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX12</i>	Zellweger syndrome, PEX12-related	AR	General Population	1 in 373	95%	1 in 7,441	<1 in 10 million
<i>PEX13</i>	Zellweger spectrum disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX14</i>	Zellweger spectrum disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX16</i>	Zellweger spectrum disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX19</i>	Zellweger spectrum disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX2</i>	Zellweger syndrome, PEX2-related	AR	General Population	1 in 500	95%	1 in 9,981	<1 in 10 million
			Ashkenazi Jewish Population	1 in 123	95%	1 in 2,441	1 in 1,200,972
<i>PEX26</i>	Zellweger syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX3</i>	Zellweger spectrum disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX5</i>	Zellweger spectrum disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PEX6</i>	Zellweger syndrome, PEX6-related	AR	General Population	1 in 280	99%	1 in 27,901	<1 in 10 million
			Yemenite Jewish Population	1 in 18	99%	1 in 1,701	1 in 122,472
<i>PEX7</i>	Rhizomelic chondrodysplasia punctata, type 1	AR	General Population	1 in 158	99%	1 in 15,701	1 in 9,923,032
<i>PFKM</i>	Glycogen storage disease VII	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 120	99%	1 in 11,901	1 in 5,712,480
<i>PGK1</i>	Phosphoglycerate kinase 1 deficiency	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>PGM3</i>	Immunodeficiency 23	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PHF8</i>	X-linked intellectual disability, Siderius type	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>PHGDH</i>	Phosphoglycerate dehydrogenase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 280	98%	1 in 13,951	<1 in 10 million
<i>PHKA1</i>	Glycogen storage disease type IXd	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>PHKA2</i>	Glycogen storage disease type IXa	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>PHKB</i>	Glycogen storage disease type IXb	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PHKG2</i>	Glycogen storage disease type IXc	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PHYH</i>	Refsum disease	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PIGN</i>	Multiple congenital anomalies hypotonia seizures syndrome 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PIP5K1C</i>	Lethal congenital contractural syndrome 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PJVK</i>	Nonsyndromic hearing loss 59	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PKHD1</i>	Polycystic kidney disease, PKHD1-related	AR	General Population	1 in 70	98%	1 in 3,451	1 in 966,280
			Ashkenazi Jewish Population	1 in 107	98%	1 in 5,301	1 in 2,268,828
<i>PLA2G6</i>	Infantile neuroaxonal dystrophy	AR	General Population	1 in 500	97%	1 in 16,634	<1 in 10 million
<i>PLEKHG5</i>	Charcot-Marie-Tooth disease type C	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PLEKHG5</i>	Distal spinal muscular atrophy type 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>PLOD1</i>	Ehlers-Danlos syndrome with kyphoscoliosis, PLOD1-related	AR	General Population	1 in 159	99%	1 in 15,801	<1 in 10 million
<i>PLOD2</i>	Bruck syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PLP1</i>	Spastic paraplegia type 2	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>PLP1</i>	Pelizaeus-Merzbacher disease	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>PMM2</i>	Congenital disorder of glycosylation type 1a	AR	General Population	1 in 63	99%	1 in 6,201	1 in 1,562,652
			Ashkenazi Jewish Population	1 in 57	99%	1 in 5,601	1 in 1,277,028
			Caucasian / European Population	1 in 71	99%	1 in 7,001	1 in 1,988,284
<i>PNP</i>	Purine nucleoside phosphorylase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PNPLA1</i>	Autosomal recessive congenital ichthyosis 10	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PNPO</i>	Pyridoxamine 5'-phosphate oxidase deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>POC1A</i>	Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>POLG</i>	Ataxia neuropathy spectrum	AR	General Population	1 in 113	95%	1 in 2,241	1 in 1,012,932
<i>POLG</i>	Progressive external ophthalmoplegia	AR	General Population	1 in 113	95%	1 in 2,241	1 in 1,012,932
<i>POLG</i>	Myocerebrohepatopathy syndrome	AR	General Population	1 in 113	95%	1 in 2,241	1 in 1,012,932
<i>POLG</i>	POLG-related disorders	AR	General Population	1 in 113	95%	1 in 2,241	1 in 1,012,932
<i>POLG</i>	Alpers-Huttenlocher syndrome	AR	General Population	1 in 113	95%	1 in 2,241	1 in 1,012,932
<i>POLH</i>	Xeroderma pigmentosum	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>POLR1C</i>	Hypomyelinating Leukodystrophy, POLR1C-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>POLR1C</i>	Treacher Collins syndrome, POLR1C-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>POMGNT1</i>	Muscular dystrophy-dystroglycanopathy	AR	General Population	1 in 462	98%	1 in 23,051	<1 in 10 million
			Finnish Population	1 in 111	98%	1 in 5,501	1 in 2,442,444
<i>POMGNT1</i>	Retinitis pigmentosa 76	AR	General Population	1 in 462	98%	1 in 23,051	<1 in 10 million
			Finnish Population	1 in 111	98%	1 in 5,501	1 in 2,442,444
<i>POMT1</i>	Muscular dystrophy-dystroglycanopathy, POMT1-related	AR	General Population	1 in 290	99%	1 in 28,901	<1 in 10 million
<i>POMT2</i>	Muscular dystrophy-dystroglycanopathy, POMT2-related	AR	General Population	1 in 371	99%	1 in 37,001	<1 in 10 million
<i>POR</i>	Antley-Bixler syndrome	AR	General Population	1 in 159	98%	1 in 7,901	1 in 5,025,036
<i>POU1F1</i>	Combined pituitary hormone deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>POU3F4</i>	X-linked hearing loss, POU3F4-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>PPIB</i>	Osteogenesis imperfecta, type IX	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PPT1</i>	Neuronal ceroid lipofuscinosis, PPT1-related	AR	General Population	1 in 368	98%	1 in 18,351	<1 in 10 million
			Caucasian / European Population	1 in 488	98%	1 in 24,351	<1 in 10 million
			Finnish Population	1 in 75	98%	1 in 3,701	1 in 1,110,300
<i>PQBP1</i>	Renpenning syndrome	XL	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PRCD</i>	Retinitis pigmentosa 36	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PRDM5</i>	Brittle cornea syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PRF1</i>	Hemophagocytic lymphohistiocytosis, familial, 2	AR	General Population	1 in 149	99%	1 in 14,801	1 in 8,821,396
<i>PRICKLE1</i>	Progressive myoclonic epilepsy, type 1B	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PRKDC</i>	PRKDC-related immunodeficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PROP1</i>	Combined pituitary hormone deficiency 2	AR	General Population	1 in 45	98%	1 in 2,201	1 in 396,180
<i>PRPS1</i>	Rosenberg-Chutorian syndrome	XL	General Population	<1 in 250,000	98%	1 in 12,499,951	<1 in 10 million
<i>PRPS1</i>	Arts syndrome	XL	General Population	<1 in 250,000	98%	1 in 12,499,951	<1 in 10 million
<i>PRPS1</i>	Non-syndromic hearing loss, PRPS1-related	XL	General Population	<1 in 250,000	98%	1 in 12,499,951	<1 in 10 million
<i>PRPS1</i>	Phosphoribosylpyrophosphate synthetase superactivity	XL	General Population	<1 in 250,000	98%	1 in 12,499,951	<1 in 10 million
<i>PSAP</i>	Metachromatic leukodystrophy due to saposin-b deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>PTPRC</i>	PTPRC related-severe combined immunodeficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PTS</i>	Tetrahydrobiopterin deficiency	AR	General Population	1 in 354	96%	1 in 8,826	<1 in 10 million
<i>PUS1</i>	Mitochondrial myopathy and sideroblastic anemia 1	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>PYGL</i>	Glycogen storage disease VI	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>PYGM</i>	Glycogen storage disease type V	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Caucasian / European Population	1 in 206	99%	1 in 20,501	<1 in 10 million
<i>QDPR</i>	Tetrahydrobiopterin deficiency, QDPR-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million



# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>RAB23</i>	Carpenter syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>RAG1</i>	Omenn syndrome, RAG1-related	AR	General Population	1 in 290	98%	1 in 14,451	1 in 16,763,160
<i>RAG2</i>	Omenn syndrome, RAG2-related	AR	General Population	1 in 137	98%	1 in 6,801	1 in 3,726,948
<i>RAPSN</i>	Congenital myasthenic syndrome, RAPSN-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RAPSN</i>	Fetal akinesia deformation sequence	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RARS2</i>	Pontocerebellar hypoplasia type 6	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>RAX</i>	Microphthalmia, isolated 3	AR	General Population	1 in 289	99%	1 in 28,801	<1 in 10 million
<i>RD3</i>	Leber congenital amaurosis 12	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RDH12</i>	Leber congenital amaurosis type 13	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Caucasian / European Population	1 in 456	98%	1 in 22,751	<1 in 10 million
<i>RDH5</i>	Fundus albipunctatus	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RFX5</i>	Bare lymphocyte syndrome type II	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RFXANK</i>	MHC class II deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RFXAP</i>	Bare lymphocyte syndrome type II	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RHAG</i>	Rh Deficiency syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RLBP1</i>	Retinal dystrophy, RLBP1-related	AR	General Population	1 in 296	98%	1 in 14,751	<1 in 10 million
			Caucasian / European Population	1 in 84	98%	1 in 4,151	1 in 1,394,736
<i>RMRP</i>	Metaphyseal dysplasia without hypotrichosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Amish Population	1 in 16	99%	1 in 1,501	1 in 96,064
			Finnish Population	1 in 76	99%	1 in 7,501	1 in 2,280,304
<i>RMRP</i>	Cartilage-Hair Hypoplasia Anauxetic Dysplasia Spectrum Disorder	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Amish Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Finnish Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RMRP</i>	Anauxetic dysplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Amish Population	1 in 16	99%	1 in 1,501	1 in 96,064
			Finnish Population	1 in 76	99%	1 in 7,501	1 in 2,280,304
<i>RMRP</i>	Cartilage-hair hypoplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Amish Population	1 in 16	99%	1 in 1,501	1 in 96,064
			Finnish Population	1 in 76	99%	1 in 7,501	1 in 2,280,304
<i>RNASEH2A</i>	Aicardi-Goutieres syndrome 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RNASEH2B</i>	Aicardi Goutieres syndrome 2	AR	General Population	1 in 217	99%	1 in 10,801	1 in 9,375,268
<i>RNASEH2C</i>	Aicardi-Goutieres syndrome 3	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ROGDI</i>	Kohlschutter-Tonz syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RP2</i>	X-linked Retinitis pigmentosa, RP2-related	XL	General Population	1 in 4,000	99%	1 in 399,901	1 in 1,600,000
<i>RPE65</i>	Retinitis pigmentosa 20	AR	General Population	1 in 228	98%	1 in 11,351	<1 in 10 million
<i>RPE65</i>	Leber congenital amaurosis 2	AR	General Population	1 in 228	98%	1 in 11,351	<1 in 10 million
<i>RPGR</i>	X-linked Retinitis pigmentosa, RPGR-related	XL	General Population	1 in 3,000	75%	1 in 11,997	1 in 48,000
<i>RPGRIP1</i>	Leber congenital amaurosis and Cone-rod dystrophy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RPGRIP1L</i>	COACH syndrome	AR	General Population	1 in 259	98%	1 in 12,901	<1 in 10 million
<i>RPGRIP1L</i>	Joubert syndrome 7	AR	General Population	1 in 259	98%	1 in 12,901	<1 in 10 million
<i>RPGRIP1L</i>	Meckel syndrome 5	AR	General Population	1 in 259	98%	1 in 12,901	<1 in 10 million
<i>RS1</i>	Juvenile retinoschisis, X-linked	XL	General Population	1 in 2,500	96%	1 in 62,476	1 in 249,956
<i>RSPH9</i>	Primary ciliary dyskinesia 12	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>RTEL1</i>	Dyskeratosis congenita type 5	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 203	99%	1 in 20,201	<1 in 10 million
<i>SACS</i>	Autosomal recessive spastic ataxia of Charlevoix-Saguenay	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			French Canadian Population	1 in 19	95%	1 in 361	1 in 27,436
<i>SAG</i>	Retinitis pigmentosa 47	AR	General Population	1 in 228	98%	1 in 11,351	<1 in 10 million
<i>SAMD9</i>	Normophosphatemic Familial Tumoral Calcinosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Yemeni Jewish Population	1 in 25	99%	1 in 2,401	1 in 240,100
<i>SAMHD1</i>	Aicardi-Goutieres syndrome	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
<i>SARS2</i>	Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SBDS</i>	Shwachman-Diamond syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SCO1</i>	Mitochondrial complex IV deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SCO2</i>	Mitochondrial complex IV deficiency	AR	General Population	1 in 150	99%	1 in 14,901	1 in 8,940,600
<i>SDCCAG8</i>	Bardet-Biedl syndrome and Senior-Loken syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SDR9C7</i>	Autosomal recessive congenital ichthyosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>SEC23B</i>	Congenital dyserythropoietic anemia, type II	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SELENON</i>	Rigid spine muscular dystrophy	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SEPSECS</i>	Pontocerebellar hypoplasia type 2D	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Moroccan/Iraqi Jewish Population	1 in 44	99%	1 in 4,301	1 in 756,976
<i>SERPINA1</i>	Alpha-1 antitrypsin deficiency	AR	General Population	1 in 33	95%	1 in 641	1 in 84,612
			Caucasian / European Population	1 in 19	95%	1 in 361	1 in 27,436
<i>SERPINF1</i>	Osteogenesis imperfecta, type VI	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SGCA</i>	Limb-girdle muscular dystrophy, type 2D	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Caucasian / European Population	1 in 288	98%	1 in 14,351	<1 in 10 million
			Finnish Population	1 in 150	98%	1 in 7,451	1 in 4,470,600
<i>SGCB</i>	Limb-girdle muscular dystrophy, type 2E	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Caucasian / European Population	1 in 406	98%	1 in 20,251	<1 in 10 million
<i>SGCD</i>	Limb-girdle muscular dystrophy, type 2F	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>SGCG</i>	Limb-girdle muscular dystrophy, type 2C	AR	General Population	1 in 381	98%	1 in 19,001	<1 in 10 million
			Moroccan Population	1 in 250	98%	1 in 12,451	<1 in 10 million
			Roma / Gypsy Population	1 in 96	98%	1 in 4,751	1 in 1,824,384
<i>SGSH</i>	Mucopolysaccharidosis IIIA (Sanfilippo syndrome A)	AR	General Population	1 in 454	98%	1 in 22,651	<1 in 10 million
			Caucasian / European Population	1 in 253	98%	1 in 12,601	<1 in 10 million
<i>SH3TC2</i>	Charcot-Marie-Tooth disease, SH3TC2-related	AR	General Population	1 in 69	99%	1 in 6,801	1 in 1,877,076
<i>SKIV2L</i>	Trichohepatoenteric syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC12A1</i>	Bartter syndrome	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>SLC12A1</i>	Bartter syndrome, type 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC12A3</i>	Gitelman syndrome	AR	General Population	1 in 100	98%	1 in 4,951	1 in 1,980,400
<i>SLC12A6</i>	Andermann syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			French Canadian Population	1 in 23	99%	1 in 2,201	1 in 202,492
<i>SLC16A2</i>	Allan-Herndon-Dudley syndrome	XL	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC17A5</i>	Sialic acid storage disorder	AR	General Population	<1 in 500	91%	1 in 5,545	<1 in 10 million
			Finnish Population	1 in 100	91%	1 in 1,101	1 in 440,400
<i>SLC19A2</i>	Thiamine-responsive megaloblastic anemia syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC19A3</i>	Biotin-responsive basal ganglia disease	AR	General Population	1 in 109	99%	1 in 5,401	1 in 2,354,836
<i>SLC1A4</i>	Spastic tetraplegia, thin corpus callosum, and progressive microcephaly syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Ashkenazi Jewish Population	1 in 106	99%	1 in 10,501	1 in 4,452,424
<i>SLC22A5</i>	Systemic primary carnitine deficiency	AR	General Population	1 in 129	99%	1 in 12,801	1 in 6,605,316
			African/African American Population	1 in 86	99%	1 in 8,501	1 in 2,924,344
			East Asian Population	1 in 77	99%	1 in 7,601	1 in 2,341,108
			Faroese Population	1 in 9	99%	1 in 801	1 in 28,836
			Pacific Islander Population	1 in 37	99%	1 in 3,601	1 in 532,948
			South Asian/Indian Population	1 in 51	99%	1 in 5,001	1 in 1,020,204
<i>SLC25A13</i>	Citrin deficiency	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			East Asian Population	1 in 65	95%	1 in 1,281	1 in 333,060
<i>SLC25A15</i>	Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome (Triple H syndrome)	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			French Canadian Population	1 in 37	99%	1 in 3,601	1 in 532,948
<i>SLC25A20</i>	Carnitine-acylcarnitine translocase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>SLC26A2</i>	Diastrophic dysplasia	AR	General Population	1 in 158	90%	1 in 1,571	1 in 992,872
			Finnish Population	1 in 50	90%	1 in 491	1 in 98,200
<i>SLC26A2</i>	Achondrogenesis, type IB	AR	General Population	1 in 158	90%	1 in 1,571	1 in 992,872
			Finnish Population	1 in 50	90%	1 in 491	1 in 98,200
<i>SLC26A2</i>	Multiple epiphyseal dysplasia	AR	General Population	1 in 158	90%	1 in 1,571	1 in 992,872
			Finnish Population	1 in 50	90%	1 in 491	1 in 98,200
<i>SLC26A2</i>	Atelosteogenesis II	AR	General Population	1 in 158	90%	1 in 1,571	1 in 992,872
			Finnish Population	1 in 50	90%	1 in 491	1 in 98,200
<i>SLC26A3</i>	Congenital secretory chloride diarrhea	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Middle-Eastern Population	1 in 57	98%	1 in 2,801	1 in 638,628
<i>SLC26A4</i>	Pendred syndrome	AR	General Population	1 in 80	98%	1 in 3,951	1 in 1,264,320
			African/African American Population	1 in 76	98%	1 in 3,751	1 in 1,140,304
			Caucasian / European Population	1 in 88	98%	1 in 4,351	1 in 1,531,552
			East Asian Population	1 in 74	98%	1 in 3,651	1 in 1,080,696
<i>SLC27A4</i>	Ichthyosis prematurity syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC2A10</i>	Arterial tortuosity syndrome	AR	General Population	1 in 300	99%	1 in 29,901	<1 in 10 million
<i>SLC2A2</i>	Fanconi-Bickel syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>SLC34A3</i>	Hereditary hypophosphatemic rickets with hypercalciuria	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC35A3</i>	Arthrogyposis, intellectual disability, and seizures	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 453	98%	1 in 22,601	<1 in 10 million
<i>SLC37A4</i>	Glycogen storage disease, type Ib	AR	General Population	1 in 158	95%	1 in 3,141	1 in 1,985,112
			Ashkenazi Jewish Population	1 in 71	95%	1 in 1,401	1 in 397,884
<i>SLC39A4</i>	Acrodermatitis enteropathica	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>SLC3A1</i>	Cystinuria, type I	AR	General Population	1 in 50	98%	1 in 2,451	1 in 490,200
			Caucasian / European Population	1 in 42	98%	1 in 2,051	1 in 344,568
<i>SLC45A2</i>	Oculocutaneous albinism, type IV	AR	General Population	1 in 159	98%	1 in 7,901	1 in 5,025,036
			Japanese Population	1 in 146	98%	1 in 7,251	1 in 4,234,584
<i>SLC46A1</i>	Hereditary folate malabsorption	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Puerto Rican Population	1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC4A1</i>	Distal Renal Tubular Acidosis	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC4A11</i>	Corneal endothelial dystrophy	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>SLC5A5</i>	Thyroid dyshormonogenesis, SLC5A5-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SLC6A19</i>	Hartnup disorder	AR	General Population	1 in 87	99%	1 in 8,601	1 in 2,993,148
<i>SLC6A8</i>	Creatine deficiency syndrome	XL	General Population	1 in 3,434	98%	1 in 171,651	1 in 686,716
<i>SLC7A7</i>	Lysinuric protein intolerance	AR	General Population	<1 in 500	95%	1 in 9,981	<1 in 10 million
			Finnish Population	1 in 122	95%	1 in 2,421	1 in 1,181,448
			Japanese Population	1 in 119	95%	1 in 2,361	1 in 1,123,836
<i>SLC7A9</i>	Cystinuria, non-type I	AR	General Population	1 in 42	98%	1 in 2,051	1 in 344,568
<i>SMARCAL1</i>	Schimke immunosseous dysplasia	AR	General Population	1 in 500	90%	1 in 4,991	1 in 9,982,000
<i>SMN1</i>	Spinal muscular atrophy	AR	General Population	1 in 54	91%	1 in 590	1 in 127,440
			African/African American Population	1 in 72	71%	1 in 246	1 in 70,848
			Ashkenazi Jewish Population	1 in 67	91%	1 in 734	1 in 196,712
			Caucasian / European Population	1 in 47	95%	1 in 921	1 in 173,148
			East Asian Population	1 in 59	93%	1 in 830	1 in 195,880
			Latino Population	1 in 68	90%	1 in 671	1 in 182,512
			Sephardic Jewish Population	1 in 34	96%	1 in 826	1 in 112,336
<i>SMN1</i>	Spinal muscular atrophy silent carrier	AR	General Population	1 in 54	91%	1 in 590	1 in 127,440
<i>SMPD1</i>	Niemann-Pick disease, type A/B	AR	General Population	1 in 250	95%	1 in 4,981	1 in 4,981,000
			Ashkenazi Jewish Population	1 in 115	95%	1 in 2,281	1 in 1,049,260
			Latino Population	1 in 106	95%	1 in 2,101	1 in 890,824
<i>SNAP29</i>	Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SNX10</i>	Osteopetrosis 8	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SP110</i>	Hepatic venoocclusive disease with immunodeficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SPATA7</i>	Leber congenital amaurosis (LCA) and juvenile retinitis pigmentosa (RP)	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SPG11</i>	SPG11-related Neuromuscular Disorders	AR	General Population	1 in 159	99%	1 in 15,801	<1 in 10 million
<i>SPG21</i>	Mast syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SPG7</i>	Spastic paraplegia type 7	AR	General Population	1 in 159	99%	1 in 15,801	<1 in 10 million
<i>SPINK5</i>	Netherton syndrome	AR	General Population	1 in 224	99%	1 in 23,301	<1 in 10 million
			Ashkenazi Jewish Population	1 in 17	99%	1 in 1,601	1 in 108,868
<i>SPR</i>	Sepiapterin Reductase Deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SRD5A2</i>	5-alpha reductase deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>ST3GAL5</i>	Salt and pepper developmental regression syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>STAR</i>	Lipoid congenital adrenal hyperplasia	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>STK4</i>	Combined immunodeficiency due to STK4 deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>STX11</i>	Familial hemophagocytic lymphohistiocytosis	AR	General Population	1 in 112	99%	1 in 11,101	1 in 4,973,248
<i>STXBP2</i>	Familial hemophagocytic lymphohistiocytosis	AR	General Population	1 in 112	99%	1 in 11,101	1 in 4,973,248
<i>SUCLA2</i>	Mitochondrial DNA depletion syndrome 5	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SUMF1</i>	Multiple sulfatase deficiency	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
			Ashkenazi Jewish Population	1 in 320	98%	1 in 15,951	<1 in 10 million
<i>SUOX</i>	Sulfite oxidase deficiency	AR	General Population	1 in 300	99%	1 in 29,901	1 in 13,395,648
<i>SURF1</i>	Charcot-Marie-Tooth disease, SURF1-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>SURF1</i>	Leigh syndrome, SURF1-related	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>SYN1</i>	X-linked epilepsy with variable learning disabilities	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>SYNE4</i>	Autosomal recessive deafness 76	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TAT</i>	Tyrosinemia, type II	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
<i>TAZ</i>	Barth syndrome	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>TBCE</i>	Hypoparathyroidism-retardation-dysmorphism syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TBX19</i>	Adrenocorticotrophic hormone deficiency	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TCIRG1</i>	Osteopetrosis 1	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
<i>TCTN1</i>	Joubert syndrome 13	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TCTN2</i>	Meckel syndrome 8	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
			Ethiopian Jewish Population	1 in 42	99%	1 in 4,101	1 in 688,968
			Yemenite Jewish Population	1 in 78	99%	1 in 7,701	1 in 2,402,712
<i>TCTN2</i>	Joubert syndrome 24	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TCTN3</i>	Joubert syndrome 18	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TECPR2</i>	Spastic paraplegia 49	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>TERT</i>	Dyskeratosis congenita type 4	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TF</i>	Atransferrinemia	AR	General Population	1 in 116	99%	1 in 11,501	1 in 5,336,464
<i>TFR2</i>	Hemochromatosis, type 3	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>TG</i>	Thyroid dysmorphogenesis, TG-related	AR	General Population	1 in 241	99%	1 in 24,001	<1 in 10 million
<i>TGM1</i>	Congenital ichthyosis	AR	General Population	1 in 224	95%	1 in 4,461	1 in 3,997,056
<i>TH</i>	Segawa syndrome	AR	General Population	1 in 224	98%	1 in 11,151	1 in 9,991,296
<i>THOC2</i>	X-linked Intellectual disability, THOC2-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>TK2</i>	Mitochondrial DNA depletion syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMC1</i>	Nonsyndromic hearing loss 7	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMEM138</i>	Joubert syndrome 16	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMEM216</i>	Joubert syndrome 2	AR	General Population	1 in 141	98%	1 in 7,001	1 in 3,948,564
			Ashkenazi Jewish Population	1 in 92	98%	1 in 4,551	1 in 1,674,768
<i>TMEM216</i>	Meckel syndrome 2	AR	General Population	1 in 141	98%	1 in 7,001	1 in 3,948,564
			Ashkenazi Jewish Population	1 in 92	98%	1 in 4,551	1 in 1,674,768
<i>TMEM231</i>	Joubert syndrome 20	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMEM237</i>	Joubert syndrome 14	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMEM38B</i>	Osteogenesis imperfecta, type XIV	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMEM67</i>	COACH syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMEM70</i>	Mitochondrial complex V deficiency type 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TMPRSS3</i>	Nonsyndromic hearing loss, TMPRSS3-related	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>TNFSF11</i>	Osteopetrosis 2	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
<i>TNXB</i>	Ehlers-Danlos-like syndrome due to tenascin-X deficiency	AR	General Population	1 in 28	99%	1 in 2,701	1 in 302,512
<i>TPO</i>	Thyroid dysmorphogenesis, TPO-related	AR	General Population	1 in 373	99%	1 in 37,201	<1 in 10 million
<i>TPP1</i>	Neuronal ceroid lipofuscinosis, TPP1-related	AR	General Population	1 in 252	97%	1 in 8,368	1 in 8,434,944
			French Canadian Population	1 in 53	97%	1 in 1,734	1 in 367,608
<i>TRAPPC11</i>	Limb-girdle muscular dystrophy 18	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TRDN</i>	Catecholaminergic polymorphic ventricular tachycardia	AR	General Population	1 in 354	98%	1 in 17,651	<1 in 10 million
<i>TREX1</i>	Aicardi-Goutieres syndrome 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TRHR</i>	Generalized thyrotropin-releasing hormone resistance	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TRIM32</i>	Limb-girdle muscular dystrophy, type 2H	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Hutterite Population	1 in 12	98%	1 in 551	1 in 26,448
<i>TRIM32</i>	Bardet-Biedl syndrome 11	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Hutterite Population	1 in 12	98%	1 in 551	1 in 26,448
<i>TRIM37</i>	Mulibrey nanism	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TRMU</i>	Liver failure, acute infantile	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Yemeni Jewish Population	1 in 34	98%	1 in 1,651	1 in 224,536
<i>TRPM6</i>	Hypomagnesemia 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TSEN54</i>	Pontocerebellar hypoplasia type 2A	AR	General Population	1 in 250	98%	1 in 12,451	<1 in 10 million
<i>TSM</i>	Combined oxidative phosphorylation deficiency, TSM-related	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Finnish Population	1 in 80	98%	1 in 3,951	1 in 1,264,320

# Beacon Carrier Screening Supplemental Table

Gene	Condition	Inheritance	Ethnicity	Carrier Rate	Detection Rate	Post-test Carrier Probability*	Residual Risk*
<i>TSHB</i>	Congenital hypothyroidism, TSHB-related	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TSHR</i>	Congenital hypothyroidism, TSHR-related	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TTC37</i>	Trichohepatoenteric syndrome	AR	General Population	1 in 500	98%	1 in 24,951	<1 in 10 million
<i>TTC7A</i>	Gastrointestinal defects and immunodeficiency syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TTC8</i>	Bardet-Biedl syndrome 8	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TTPA</i>	Ataxia with isolated vitamin E deficiency	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Caucasian / European Population	1 in 267	90%	1 in 2,661	1 in 2,841,948
<i>TULP1</i>	Leber congenital amaurosis 15	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TULP1</i>	Retinitis pigmentosa 14	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>TYMP</i>	Mitochondrial neurogastrointestinal encephalopathy (MNGIE) disease	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>TYR</i>	Oculocutaneous albinism types 1A and 1B	AR	General Population	1 in 20	99%	1 in 1,901	1 in 152,080
<i>TYRP1</i>	Oculocutaneous albinism, type III	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			African Population	1 in 47	98%	1 in 2,301	1 in 432,588
<i>UGT1A1</i>	Crigler-Najjar syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>UNC13D</i>	Familial hemophagocytic lymphohistiocytosis type 3	AR	General Population	1 in 149	99%	1 in 14,801	1 in 8,821,396
<i>UPF3B</i>	Lujan-Fryns syndrome, UPF3B-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>USH1C</i>	Usher syndrome, type IC	AR	General Population	1 in 353	90%	1 in 3,521	1 in 4,971,652
			French Canadian Population	1 in 227	90%	1 in 2,261	1 in 2,052,988
<i>USH1C</i>	Non-syndromic hearing loss, USH1C-related	AR	General Population	1 in 353	90%	1 in 3,521	1 in 4,971,652
			French Canadian Population	1 in 227	90%	1 in 2,261	1 in 2,052,988
<i>USH1G</i>	Usher syndrome type IG	AR	General Population	1 in 434	99%	1 in 43,301	<1 in 10 million
<i>USH2A</i>	Usher syndrome, type 2A	AR	General Population	1 in 126	96%	1 in 3,126	1 in 1,575,504
			Caucasian / European Population	1 in 73	96%	1 in 1,801	1 in 525,892
			Ashkenazi Jewish Population	1 in 35	99%	1 in 3,401	1 in 476,140
			Iranian Jewish Population	1 in 60	99%	1 in 5,901	1 in 1,416,240
<i>VDR</i>	Vitamin D-dependent rickets, type 2A	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>VLDLR</i>	Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>VPS13A</i>	Choreoacanthocytosis	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>VPS13B</i>	Cohen syndrome	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>VPS45</i>	Severe congenital neutropenia, VPS45-related	AR	General Population	1 in 224	98%	1 in 11,151	1 in 9,991,296
<i>VPS53</i>	Pontocerebellar hypoplasia type 2E	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
			Moroccan Jewish Population	1 in 37	98%	1 in 1,801	1 in 266,548
<i>VRK1</i>	Pontocerebellar hypoplasia type 1A	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>VSX2</i>	Microphthalmia with or without coloboma	AR	General Population	1 in 91	98%	1 in 4,501	1 in 1,638,364
<i>WAS</i>	Thrombocytopenia, X-linked	XL	General Population	1 in 125,000	99%	1 in 12,499,901	<1 in 10 million
<i>WAS</i>	Severe congenital neutropenia, WAS-related	XL	General Population	1 in 125,000	99%	1 in 12,499,901	<1 in 10 million
<i>WAS</i>	Wiskott-Aldrich syndrome	XL	General Population	1 in 125,000	99%	1 in 12,499,901	<1 in 10 million
<i>WHRN</i>	Usher syndrome type 2D	AR	General Population	1 in 282	99%	1 in 28,101	<1 in 10 million
<i>WISP3</i>	Progressive pseudorheumatoid dysplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>WNT1</i>	Osteogenesis imperfecta type 15	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>WNT10A</i>	Schopf-Schulz-Passarge syndrome	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>WNT10A</i>	Odontonychoodermal dysplasia	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>WRN</i>	Werner syndrome	AR	General Population	1 in 308	98%	1 in 15,351	<1 in 10 million
			Caucasian / European Population	1 in 112	98%	1 in 5,551	1 in 2,486,848
			Japanese Population	1 in 71	98%	1 in 3,501	1 in 994,284
<i>XPA</i>	Xeroderma pigmentosum, group A	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
			Japanese Population	1 in 74	99%	1 in 7,301	1 in 2,161,096
<i>XPC</i>	Xeroderma pigmentosum, group C	AR	General Population	1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ZAP70</i>	Infantile-onset multisystem autoimmune disease type 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ZAP70</i>	Immunodeficiency 48	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ZBTB24</i>	Immunodeficiency-centromeric instability-facial anomalies syndrome 2	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ZDHHC9</i>	X-linked intellectual disability, ZDHHC9-related	XL	General Population	<1 in 50,000	99%	1 in 4,999,901	<1 in 10 million
<i>ZFYVE26</i>	Spastic paraplegia 15	AR	General Population	<1 in 500	98%	1 in 24,951	<1 in 10 million
<i>ZNF469</i>	Brittle cornea syndrome 1	AR	General Population	<1 in 500	99%	1 in 49,901	<1 in 10 million
<i>ZNF711</i>	X-linked intellectual disability, ZNF711-related	XL	General Population	<1 in 50,000	93%	1 in 714,272	1 in 2,857,143

\* For genes that have tested negative

† The carrier frequency for heterozygous alpha thalassemia carriers (-/-) is described in rows marked with a dagger symbol. The carrier frequency for alpha thalassemia trait cis (-/-) is 1 in 1000. Abbreviations: AR, autosomal recessive; XL, X-linked